Curriculum Vitae

ASSOCIATE PROF. DR. MARNIZA BINTI SAAD

Associate Professor
  • Department of Oncology Clinical
    Faculty of Medicine
  • marniza
  • +60379492185

BIOGRAPHY


Marniza Saad is a Consultant Clinical Oncologist at the Department of Clinical Oncology, University Malaya Medical Centre (UMMC) Kuala Lumpur, Malaysia, since 2006. She also holds the Associate Professor post at the Faculty of Medicine, University Malaya (UM) Kuala Lumpur. She obtained her Medical Degree from University of Wales College of Medicine, Cardiff, United Kingdom in 1997. She completed her general medical training within the South Wales Medical Rotation in 2000. In 2001 she joined UM as a trainee lecturer in Oncology. She pursued her formal training as clinical oncologist at the Velindre Cancer Centre in Cardiff, UK from 2002 to 2006 and was awarded the Fellowship of Royal College of Radiologists (Clinical Oncology) in 2006. She is now the supervisor and internal examiner for the Master of Clinical Oncology programme in UM since May 2006. Working within the department Education Committee, she has deep passion for education and training of future oncologists in Malaysia. She was the Head of Department of Clinical Oncology UMMC from 2013 to 2015. During this time she was overseeing the development of Stereotactic Radiosurgery/Radiotherapy (SRS/SRT) and Intensity Modulated Radiotherapy (IMRT) with the designated expert teams, until successful initiation of the services in UMMC in May and September 2015, respectively. She is currently in the UMMC Intra-Operative Radiotherapy Working Group to introduce the service in UMMC in the near future. She is an Exco Committee member for Malaysia Oncological Society since 2013. She is a member of College of Radiology Academy of Medicine Malaysia and European Society for Medical Oncology. Her areas of special interest include genitourinary cancer, sarcoma, breast and gastrointestinal cancers. She is the principle investigator for several international clinical trials mainly in urological cancers and regularly speaks in the areas of her interest at both local and international conferences. 

AREAS OF EXPERTISE


  • RADIOTHERAPY, CLINICAL ONCOLOGY, CHEMOTHERAPY, HORMONAL THERAPY, TARGETED THERAPY, GENITOURINARY CANCER, SOFT TISSUE SARCOMA, BONE SARCOMA, GASTROINTESTINAL CANCER, BREAST CANCER

ACADEMIC QUALIFICATION


  • FRCR, (Clinical Oncology)
    Royal College of Radiologist, London
  • MBBCh, (PERUBATAN DAN PEMBEDAHAN)
    University of Wales College of Medicine, Cardiff

ADMINISTRATIVE DUTIES


  • Committee Members
    04 Jan 2023 - 31 Dec 2024 (National)
  • Coordinator for Part 2 programme Masters of Clinical Oncology
    20 May 2006 - present (Department of Oncology, Faculty of Medicine)
  • Lead for Clinical Oncology National Curriculum Project
    03 Jun 2016 - present (National)
  • Clinical Oncology Specialty Committee for Masters of Clinical Oncology
    01 Jan 2009 - present (National)
  • Course Coordinator
    01 Jan 2022 - 31 Dec 2022 (National)
  • Master of Clinical Oncology Part 2 & Research Coordinator
    01 Jul 2019 - 30 Jun 2020 (University Malaya)
  • Education Committee Member Department of Clinical Oncology UMMC
    01 Sep 2015 - 31 Aug 2017 ()
  • Clinical Oncology Specialty Committee for Masters of Clinical Oncology
    01 Sep 2015 - 31 Aug 2017 ()
  • Clinical Oncology National Curriculum Writing Group.
    01 Apr 2015 - 30 Jun 2017 (National)
  • Committee Member of Jawatankuasa Ijazah Tinggi Fakulti Perubatan
    01 Oct 2014 - 01 Jun 2016 (Dean Office, Faculty of Medicine)
  • Chairperson for Pharm UMMC Committee
    01 Sep 2015 - 29 Feb 2016 ()
  • Chairperson for Hospital Infection Control Committee UMMC
    01 Sep 2015 - 29 Feb 2016 ()
  • Head
    01 Aug 2014 - 31 Aug 2015 (Clinical Oncology Unit, Faculty of Medicine)
  • MAC Committee Member
    01 Nov 2011 - 31 Aug 2015 (University Malaya)
  • Committee Member for Radiation Protection Committee
    01 Apr 2014 - 31 Aug 2015 (Faculty)
  • Chairperson for Clinical Oncology Trust Fund
    01 Sep 2013 - 31 Aug 2015 (Dean Office, Faculty of Medicine)
  • Head
    01 Sep 2013 - 30 Jun 2014 (Clinical Oncology Unit, Faculty of Medicine)
  • Research Coordinator for Master of Clinical Oncology
    01 Jun 2012 - 08 Jul 2013 (University Malaya)
  • Member in Quality Improvement Team Project on Nutritional Assessment for Patients with Cancer. 2010.
    30 Sep 2010 - 04 Jan 2010 (Department of Oncology, Faculty of Medicine)
  • Committee member for Curriculum Development for Nursing Programmes.
    15 Nov 2006 - 30 Jun 2006 (Department of Nursing Science, Faculty of Medicine)

MEMBERSHIPS


  • CANCER ECHO UM - COMMITTEE MEMBER, COMMITTEE MEMBER
    Since 2021 (University)
  • ESMO - MEMBER, MEMBER
    2020 to 2024 (International)
  • MEMBER - NATIONAL SPECIALIST REGISTER MALAYSIA, MEMBER
    Since 2012 (National)
  • AMM - MEMBER, COLLEGE OF RADIOLOGY, ACADEMY OF MEDICINE MALAYSIA, MEMBER
    Since 2009 (National)
  • MALAYSIA ONCOLOGICAL SOCIETY, LIFE MEMBERSHIP
    Since 2006 (National)
  • FARO - EDUCATION AND TRAINING COMMITTEE , COMMITTEE MEMBER
    2021 to 2022 (International)
  • ASCO - MEMBER, MEMBER
    2021 to 2022 (International)

AWARD AND STEWARDSHIP


  • Special Recognition for Excellent Service for COVID19 at the peak of the Pandemic in Malaysia.
    University Malaya Medical Centre, 2021 (University)
  • Certificate of Appreciation - HUNA (Ho Chi Minh Urology and Nephrology Association) Annual Meeting - Banmethuot, Vietnam - June 2019
    HUNA Vietnam, 2019 (International)
  • Certificate of Appreciation - Prostate Cancer Meeting - Cho Ray Hospital, Vietnam June 2019.
    Cho Ray Hospital, Ho Chih Minh, Vietnam, 2019 (International)
  • Certificate of Appreciation : Oncology Colloquium 2-3 Feb 2018, UM.
    Malaysian Medic International, 2018 (National)
  • Certificate of Appreciation : Sarcoma MDT Preceptorship, 14-15 Jul 2017, SINGAPORE.
    National Cancer Centre, Singapore., 2017 (International)
  • Certificate of Appreciation : Masterclass in Systemic Cancer Therapy (MSCT2017), 4-5 March 2017, UMMC.
    UMMC, 2017 (National)
  • Certificate of Appreciation : MMI Specialising Opportunities Symposium 2 -Specialising in Oncology, MMI, 29-30 Apr 2017, KUALA LUMPUR.
    MMI (Malaysian Medics International), 2017 (National)
  • Certificate of Appreciation, Malaysian Oncological Society : ASCOMOS 2017
    MOS, 2017 (National)
  • Anugerah Perkhidmatan Cemerlang Universiti Malaya tahun 2016.
    University Malaya, 2017 (University)
  • Best Lecturer for Clinical Oncology Session 2015/2016.
    University Malaya, 2017 (University)
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2017 (University)
  • Letter of Appreciation
    University Malaya, 2016 (University)
  • Certificate of Appreciation
    College of Surgeons Malaysia, 2016 (National)
  • Certificate of Appreciation
    Malaysian Urological Association, 2016 (National)
  • Certificate of Appreciation
    Malaysian Oncological Society, 2016 (National)
  • Certificate of Appreciation
    Malaysian Urological Association, 2016 (National)
  • Certificate of Appreciation
    Malaysian Orthopaedic Association, 2016 (National)
  • Certificate of Appreciation : Capecitabine Preceptorship April 2015.
    UMMC, 2015 (International)
  • Featured as an expert panel in 23rd Asia Pacific Cancer Conference Bulletin : Heterogeneity of Prostate Cancer - A Guide to Treatment Choice.
    APCC, 2015 (International)
  • Certificate of Appreciation : Invited panel at the First UMMC Breast Cancer Public Forum 18 Oct 2014.
    UMMC, 2014 (National)
  • Certificate of Appreciation : Scientific Committee for Colorectal Cancer Workshop 29 March 2014.
    Department of Clinical Oncology UMMC, 2014 (University)
  • Certificate of Appreciation : Invited Faculty in the Section of Uro-Oncology Forum 2014 7-8 June 2014
    MUA, 2014 (National)
  • Expert panel on national radio station BFM, The Bigger Picture - Kidney cancer and its treatment development. http://www.bfm.my/marniza-saad-kidney-cancer.html , (National), 26-Jun-14 until 26-Jun-14
    BFM Radio, 2014 (National)
  • Certificate of Appreciation : Coordinator for Oncology Track at Musculoskeletal Imaging Conference
    College of Radiology Malaysia, 2013 (International)
  • Expert Panel in Health and Beauty magazine on`Targeted therapies for Cancer Care'.
    Health and Beauty, 2013 (National)
  • Expert Panel in Health Today Magazine on 'Treating Prostate Cancer'
    Health Today, 2013 (National)
  • Certificate of Appreciation : Scientific Committee and Chair at ASCOMOS 2013
    Malaysia Oncology Society, 2013 (International)
  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2011 (University)
  • Sijil Perkhidmatan Cemerlang.
    University Malaya, 2011 (University)
  • Expert Panel on Helo Malaysia at Bernama TV : Breast Cancer.
    Bernama TV, 2009 (National)
  • Sijil Perkhidmatan Cemerlang kepada Pesakit.
    University Malaya Medical Centre., 2008 (University)

PUBLICATIONS


Article in Journal
  1. Jasmine Lim, Mizuki Onozawa, Marniza Saad, Teng Aik Ong,| The A-CaP (Asian Prostate Cancer) Study, J-CaP (Japan Prostate Cancer Study Group), M-CaP (Malaysia Prostate Cancer Study Group), Rohan Malek, Hideyuki Akaza. Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high-and middle-income Asian countries. Cancer Science, March 2021. DOI: 10.1111/cas.14889
  2. Lim, J., Amantakul, A., Shariff, N., Lojanapiwat, B., Alip, A., Ong, T. A., Thevarajah, S., Ahmayuddin, F., Mathew, A., Sriplakich, S., Vuthiwong, J., Chong, F., & Saad, M. (2020). Clinical outcomes of abiraterone acetate and predictors of its treatment duration in metastatic castration-resistant prostate cancer: Real-world experience in the Southeast Asian cohort. Cancer medicine, 9(13), 4613 4621. https://doi.org/10.1002/cam4.3101
  3. N. B. Jalil, P. Y. Lee, M. Z. Nor Afiah, K. L. Abdullah, F. N. S. Mohd Azizi, N. N. S. Abdul Rassip, T. A. Ong, C. J. Ng, Y. K. Lee, A. T. Cheong, A. H. Razack, M. SAAD, A. Alip, R. Malek, M. Sundram, S. Omar, J. R. Sathiyananthan, P. Kumar. Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country, Journal of Cancer Education, June 2020, https://doi.org/10.1007/s13187-020-01801-6
  4. Nirmala Bhoo-Pathy, Chiu-Wan Ng, Gerard Chin-Chye Lim, Nor Saleha Ibrahim Tamin, Richard Sullivan, Nanthini Thevi Bhoo-Pathy, Matin Mellor Abdullah, Merel Kimman, Shridevi Subramaniam, MARNIZA SAAD, Nur Aishah Taib, Kian-Meng Chang, Pik-Pin Goh, Cheng-Har Yip, Financial Toxicity After Cancer in a Setting With Universal Health Coverage: A Call for Urgent Action. Journal of Onccology Practice, Mar 2019.
  5. Nurul Aqilah Mohd Nor, Nur Aishah TaibEmail author, MARNIZA SAAD, Hana Salwani Zaini, Zahir Ahmad, Yamin Ahmad and Sarinder Kaur Dhillon. (2019). Development of electronic medical records for clinical and research purposes: the breast cancer module using an implementation framework in a middle income country- Malaysia. BMC Bioinformatics201919 (Suppl 13) :402
  6. Saad, M., Alip, A., Lim, J., Abdullah, M. M., Chong, F., Chua, C. B., Ismail, F., Khong, R. K., Lim, C. S., Loh, C. S., Malek, R., Mohd Ghani, K. A., Md Noor, I., Md Yusoff, N. A., Nasuha, N. A., Razack, A., Soo Hoo, H. F., Sundram, M., Tan, H. M., Thiagarajan, M., The, G. C., Voon, P. J., & Ong, T. A. (2019). Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. BJU international, 124(3), 373 382. https://doi.org/10.1111/bju.14807
  7. Abd Ghafar, N. K., Alip, A., Ong, T. A., Yap, N. Y., & Saad, M. (2018). Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience. Journal of cancer research and therapeutics, 14(6), 1303 1311. https://doi.org/10.4103/0973-1482.189247
  8. Edmund Chiong, Declan G. Murphy, Hideyuki Akaza, Nicholas C. Buchane, Byung Ha Chung , Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Chi-Fai Ng, Teng Ong, Yeong-Shiau Pu, MARNIZA SAAD, Kathryn Schubach, Levent Turkeri, Rainy Umbas, Vu Le Chuyen, Scott Williams, Ding-Wei Ye, ANZUP Cancer Trials Group and Ian D. Davis. Management of patients with advanced prostate cancer in the Asia Pacific region: real-world consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. BJU International, 2018.
  9. Ina Shaliny Duraisamy, MARNIZA SAAD, Adlinda Alip. Single vs multiple fraction palliative radiotherapy for uncomplicated painful bone metastases treated at University of Malaya Medical Centre: A single institutional Malaysian experience. Aging Medicine, 2018;1:133 140.
  10. MARNIZA SAAD, Flora Li Tze Chong, Anita Zarina Bustam, Gwo Fuang Ho, Rozita Abdul Malik, Wan Zamaniah Wan Ishak, Vincent Chee Ee Phua, Mastura Md Yusof, Ning Yi Yap, Adlinda Alip. The efficacy and tolerability of scalp cooling in preventing chemotherapy induced alopecia in patients with breast cancer receiving anthracycline and taxane based chemotherapy in an Asian setting. Ind Journal of Cancer, 2018;157-161.
  11. Yap, N.Y., Khoo, W.T., Perumal, K., Ng, K.A., Rajandram,R., Alip, A., SAAD, M. and Ong, T.A. (2018), Practical updates in medical therapy for advanced and metastatic renal cell carcinoma. Urological Science, 29 (3), 120-8.
  12. Bhoo-Pathy NT, Inaida S2, Tanaka S, Taib NA3, Yip CH, SAAD M, Kawakami K, Bhoo-Pathy N. Impact of adjuvant chemotherapy on survival of women with T1N0M0, hormone receptor negative breast cancer. Cancer Epidemiology Jun 2017;48:56-61. doi: 10.1016/j.canep.2017.03.007. Epub 2017 Apr 1.
  13. Karim Fizazi, M.D., Ph.D., NamPhuong Tran, M.D., Luis Fein, M.D., Nobuaki Matsubara, M.D., Alfredo Rodriguez Antolin, M.D., Ph.D., Boris Y. Alekseev, M.D., Mustafa zg ro lu, M.D., Dingwei Ye, M.D., Susan Feyerabend, M.D., Andrew Protheroe, M.D., Ph.D., Peter De Porre, M.D., Thian Kheoh, Ph.D., Youn C. Park, Ph.D., Mary B. Todd, D.O., and Kim N. Chi, M.D., for the LATITUDE INVESTIGATORS*. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New Eng J Med, 2017.
  14. Moradi, F., Ung, N.M., Khandaker, M.U., Mahdiraji, G.A., SAAD, M., Malik, R.A., Bustam, A.Z., Zaili, Z. and Bradley, D.A.,(2017). Monte Carlo skin dose simulation in intraoperative radiotherapy of breast cancer using spherical applicators. Physics in medicine and biology. 62, 6550-66.
  15. Nor Faissal Yasin1, Vivek Ajit Singh, MARNIZA SAAD, Effat Omar. Which is the best method of sterilization for recycled bone autograft in rabbit. BMC Cancer (2015) 15:289.
  16. Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, MARNIZA SAAD, Adlinda Alip, Wan Zamaniah Wan Ishak. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
  17. Weng Heng Tang, Adlinda Alip, MARNIZA SAAD, Vincent Chee Ee Phua, Hari Chandran, Yi Hang Tan,Yan Yin Tan, Voon Fong Kua, Mohamed Ibrahim Wahid, Lye Mun Tho. Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective
  18. Yasin, N. F., Singh, V. A., Saad, M., & Omar, E. (2015). Which is the best method of sterilization for recycled bone autograft in limb salvage surgery: a radiological, biomechanical and histopathological study in rabbit. BMC cancer, 15(1), 289. (Tier 2, Impact Factor = 3.362)
  19. M.Y. Mastura, S. MARNIZA, W.I. Wan Zamaniah, P. Vincent, A.M. Rozita, A. Adlinda, G.F. Ho. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series. European Journal of Cancer 05/2014; 50:e48-e49.
  20. M.Y. Mastura, S. MARNIZA, W.I. Wan Zamaniah, P. Vincent, A.M. Rozita, A. Adlinda, G.F. Ho. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a South East Asian country: A case series. European Journal of Cancer 05/2014; 50:e48-e49. DOI: 10.1016/j.ejca.2014.03.184 (ISI-Cited Publication)
  21. WI Wan Zamaniah, MY Mastura, CE Phua, A Adlinda, S MARNIZA, AM RozitaDefinitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience. Asian Pac J Cancer Prev, 15 (20), 8987-8992
  22. Chee Ee Phua, Anita Zarina Bustam, Mastura Md Yusof, MARNIZA SAAD, Cheng-Har Yip, Nor Aishah Taib and Char Hong Ng. 2012 Risk of treatment related death (TRD) with adjuvant chemotherapy for breast cancer: A study in University Malaya Medical Centre (UMMC). Journal of Cancer Therepeutics & Research 1: 13
  23. Phua Chee Ee, Anita Zarina Bustam,Mastura Md Yusof, MARNIZA SAAD,Yip Cheng-Har, Nor Aishah Taib, Ng Char Hong, Teh Yew Ching 2012. Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting. Asia Pacific Journal of Cancer Prevention; 13(9), 4623-4626.
  24. Ajit Singh V, Nagalingam J, SAAD M, Pailoor J, 2010. Which is the best method of sterelisation of tumour bone for reimplantation? A biomechanical and histopathological study. Bio-Medical Engineering OnLine 2010, 9:48.
  25. Hoong-Yin Chong, Nur Aishah Taib, Sanjay Rampal, MARNIZA SAAD, Anita Zarina Bustam, Cheng-Har Yip. Treatment options for locally advanced breast cancer - experience in an Asian tertiery hospital. APJCP, 11:2010;1-5.
  26. Lau Peng Choong, Nur Aishah Mohd Taib, Sanjay Rampal, MARNIZA SAAD, Anita Zarina Bustam, Yip Cheng Har. High tumour stage and margin clearance are still important prognostic factors for post-mastectomy locoregional recurrence in Malaysia. APJCP,11:2010;1409-1416.
  27. Rozita AM, MARNIZA S, Mastura MY, Wan Zamaniah WI, Yip CH, Taib NA, 2010. Patterns of breast cancer relapse at University of Malaya Medical Centre, JUMMEC 2010:13 (1):24-32.
Scopus
  1. Chiong E., Murphy D.G., Buchan N.C., Chua M.L.K., Hakim L., Hamid A.R., Hong S.K., Horvath L.G., Kanesvaran R., Khochikar M., Letran J., Lojanapiwat B., Malek R., Ng A.C.F., Vinh N.T., Pang S.-T., Poon D.M.C., Ong T.A., Saad M., Schubach K., Shiroki R., Turkeri L., Williams S., Wong A., Ye D., Davis I.D. (2022). Managing advanced prostate cancer in the Asia Pacific region: Real-world application of Advanced Prostate Cancer Consensus Conference 2019 statements, Asia-Pacific Journal of Clinical Oncology. 18(6), 686-695. doi:10.1111/ajco.13722
  2. Gan G.G., Tey K.W.F., Mat S., Saad M., Bee P.C., Malik R.A., Ho G.F., Ng C.G. (2022). Quality of Life of Family Caregivers of Cancer Patients in a Developing Nation, Asian Pacific journal of cancer prevention : APJCP. 23(11), 3905-3914. doi:10.31557/APJCP.2022.23.11.3905
  3. Jalil N.B., Lee P.Y., Nor Afiah M.Z., Abdullah K.L., Azizi F.N.S.M., Rassip N.N.S.A., Ong T.A., Ng C.J., Lee Y.K., Cheong A.T., Razack A.H., Saad M., Alip A., Malek R., Sundram M., Omar S., Sathiyananthan J.R., Kumar P. (2022). Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country, Journal of Cancer Education. 37(1), 169-178. doi:10.1007/s13187-020-01801-6
  4. Kanesvaran R., Castro E., Wong A., Fizazi K., Chua M.L.K., Zhu Y., Malhotra H., Miura Y., Lee J.L., Chong F.L.T., Pu Y.-S., Yen C.-C., Saad M., Lee H.J., Kitamura H., Prabhash K., Zou Q., Curigliano G., Poon E., Choo S.P., Peters S., Lim E., Yoshino T., Pentheroudakis G. (2022). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer, ESMO Open. 7(4). doi:10.1016/j.esmoop.2022.100518
  5. Saad M., Umbas R., Chiong E., Kanesvaran R. (2022). Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review, Therapeutic Advances in Medical Oncology. 14. doi:10.1177/17588359221131525
  6. Song C.V., Yip C.-H., Taib N.A.M., See M.H., Teoh L.Y., Monninkhof E.M., Saad M., Uiterwaal C.S.P.M., Bhoo-Pathy N. (2022). Association Between Adherence to Clinical Practice Guidelines for Adjuvant Therapy for Breast Cancer and Survival in a Resource-Limited Setting, JCO global oncology. 8, e2100314. doi:10.1200/GO.21.00314
Chapter in Books
  1. Rajandram, R., Ong, T. A., & Saad, M. (2014). Resistance of renal cell carcinoma to targeted therapy. Advances in Drug Resistance Research. New York: Nova Science Publishers, 203-24.
Article in Proceeding
  1. Hui Shan Tan, Alvin Seng Cheong Wong, Kian Tai Chong, Siew Wei Wong, MARNIZA SAAD, Chi_Fai Ng, Shigeo Horei, Pichai Chansriwong, Min-Han Tan, Chee-Keong Toh, Quan Sing Ng, Kiat Hon Lim, Liang Seah Tay, Whee Sze Ong, Ravindran Kanesvaran. AR-V7 in Asian patientts with metastatic CRPC : A multinational, multicentre study. Journal of Clinical Oncology. February 2018;36(6_suppl):TPS401-TPS401.
  2. Audi Adawiah Sulaiman Shah*, Khairiyah Sidek, Syafirin Ab Sani, Najihah Abu Bakar, Ardif Damiri, Rizma Mohd Zaid, MARNIZA SAAD, Adlinda Alip. Efficacy and safety of pazopanib in advanced renal cell carcinoma treated at University Malaya Medical Centre (UMMC). Adv Mod Oncol Res 2017; 3(6):301. http://dx.doi.org/10.18282/amor.v3.i6.282.
  3. J Lim, N Shariff, M SAAD, A Alip, T Ong, S Lechmiannandan, F Ahmayuddin, A Mathew, FCL Tze (2017). Abiraterone in metastatic castrate resistant prostate cancer: outcome and tolerance in real-world setting. BJUI International Supplement S4: S10-11.
  4. JY-Y Khoo, A Alip, M SAAD, TA Ong. Treatment outcomes of patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC) on first line docetaxel chemotherapy at University Malaya Medical Centre. BJUI Nov 2016, 118, Supplement 3, 1-19.
  5. S Nisha, AS Syadwa,S Patricia, S Kisha, MJ Chan, TA Ong, S MARNIZA, A Adlinda. Real-World experience with abiraterone in metastatic castrate resistant prostate carcinoma in University Malaya Medical Centre. BJUI 2016, 118, Supplement 3, 1-19.
  6. SN Masyitah, AHA Razack, TA Ong, M SAAD, A Alip. The unusual kid on the block:Primary Renal Ewing Sarcoma. BJUI Nov 2016, 118, Supplement 3, 1-19.
  7. J Lim, N Bhoo-Pathy, A Alip, M SAAD, TA Ong, AHA Razack. The prostate cancer profile in multiethnic Asian men. BJU International 2015, 116, Supplement 4, 1-27.
  8. NK Abd Ghafar, A Alip, TA Ong, M Saad. Efficacy and safety of first line sunitinib in patients with metastatic renal cell cancer: a Malaysian experience from a single tertiary centre. BJU International 2015, 116, Supplement 4, 1-27.
  9. MY Mastura, S MARNIZA, WI Wan Zamaniah, P Vincent, AM Rozita, A Adlinda, GF Ho. Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in Sute East Asian country : a case series. Asian Oncology Summit, Apr 2014.
  10. Mastura Md Yusof, Suhana Yusak, Wan Zamaniah Wan Ishak, Rozita Abdul Malik, Adlinda Alip, Vincent Phua Chee Ee, Marniza Saad. Outcome of Routine Radioiodine Ablation for Differentiated Thyroid Cancer in an Academic Institution. APCC Oct 2013. in Kuala Lumpur, Malaysia, 22nd Asia Pacific Cancer Confefence, 31 Oct 2013 to 02 Nov 2013, APCC, (International)
  11. MARNIZA SAAD, Tang Weng Heng, Marfu'ah Eezamuddeen. Ten year survival in metastatic renal cell carcinoma treated with repeated local treatment and sequential systemic therapy. PD-244,2012. Asian Clinical Oncology Society Conference Proceeding, 13-15 Jun 2012.

RESEARCH PROJECT


National
  1. 2022 - 2031, Merck Sharpe & Dohme (Malaysia) Sdn Bhd
    A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022) ( Principal Investigator(PI))
  2. 2021 - 2027, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) ( Principal Investigator(PI))
  3. 2021 - 2026, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304) ( Principal Investigator(PI))
  4. 2019 - 2025, Johnson & Johnson Sdn. Bhd.
    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer ( Principal Investigator(PI))
  5. 2020 - 2025, Johnson & Johnson Sdn. Bhd.
    A phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisone recombination repair(HRR)gene-mutated metastatic castration-sensitive prostate cancer(mCSPC) ( Principal Investigator(PI))
  6. 2021 - 2025, Merck Sharp & Dohme (M) Sdn. Bhd.
    An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) ( Principal Investigator(PI))
  7. 2020 - 2022, Johnson & Johnson Sdn. Bhd.
    Biomarker study to determine frequency of DNA-repair defects in men with metastatic prostate cancer. ( Principal Investigator(PI))
  8. 2014 - 2018, Roche
    A RANDOMIZED, MULTICENTRED. OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTAMSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL AS FIRST LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE PROGRESSIVE OR RECURRENT LOCALLY ADVANCED OR METASTATIC BREAST CANCER ( Consultant)
  9. 2012 - 2017, Quintiles Janseen Cilaq
    ABI-PRO- 3002 A phase 3, randamized, double-blind,placebo-controlled study of abiraterone acetate)JNJ-212082) plus prednisone in asymtomic ormildly symptomatic patients with metastaticcastration-resistant prostate cancer ( Principal Investigator(PI))
  10. 2013 - 2017, Roche
    YO28322(MetGastric Study) A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy and Safety of Onartuzumab (MetMAb) in Combination with 5-Fluorocil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients with Metastatic HER2-Negative, Met-Positive Gastroesophageal Cancer ( Consultant)
  11. 2016 - 2017, Private Funding
    A Phase III, Randomized, Open-Label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progresses after First-Line Therapy with Platinum and Fluoropyrimidine ( Consultant)
  12. 2012 - 2015, Janssen Cilag (Johnson & Johnson)
    ABI-PRO 3002 : A phase 3, randomized, double-blind, placebo-controlled study of abiraterone acetate (JNJ-212082) plus prednisone in asymptomic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. ( Principal Investigator(PI))
  13. 2009 - 2015, Ministry of Health
    Nasopharyngeal Carcinoma Treatment Outcome Database. ( Co-Researcher)
  14. 2012 - 2015, Roche
    B027952 (GATSBY Study) A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treated locally advanced or metastatic HER2-positive gastric cancer, including adenocarcinoma of the gastroesophageal function. ( Consultant)
  15. 2013 - 2015, NONE
    Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer ( Consultant)
  16. 2014 - 2015, Nova Satra Health
    Studies of Epigenetic Changes in Circulating Tumor Cells in Breast Cancer ( Consultant)
  17. 2012 - 2014, NONE
    A Randomised Multicentre, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine 1(T-DM1) versus taxane (Docetaxel or Paclitaxel)in Patients with Previouly Treated Locally Advanced or Metastatic HER2 Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction (GATSBY) ( Consultant)
  18. 2011 - 2013, High Impact Research (HIR)
    Lapatinib study Phase II open-labelstudy of preoperativeweeklypac55 litaxel and carboplatinwithlapatinib (Tykerb ) in patientswith ErB2-positive stage I-III Breastc ncer ( Consultant)
  19. 2008 - 2012, Wyeth
    An international multi-centre phase III randomised controlled trial of first line treatment of advanced renal cell carcinoma, comparing bevacizumab + interferon-alpha versus bevacizumab + torisel. ( Principal Investigator(PI))
  20. 2010 - 2012, Abbott
    Linifanib vs sorafenib for upfront treatment of advanced hepatocellular carcinoma ( Consultant)
  21. 2008 - 2012, Geran Penyelidikan Universiti Malaya (UMRG)
    Induction and concurrent chemoradiation with cetuximab for treatment of locally advanced Nasopharyngeal Carcinoma ( Consultant)
  22. 2008 - 2011, Cancer Research Centre, Ministry of Health, Malaysia
    NPC Study An open labeled, multicentre, randomized phase II trial of combination gemcitabine and carboplatin chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma. ( Consultant)
  23. 2007 - 2010, Genentech
    A phase 3 multicentre, randomised, placebo- controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer. ( Principal Investigator(PI))
  24. 2008 - 2010, Short Term Research Fund (Vote F)(PJP)
    A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study) ( Principal Investigator(PI))
Private
  1. 2023 - 2028, Exelixis, Inc.
    A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF XL092 + NIVOLUMAB VS SUNITINIB IN SUBJECTS WITH ADVANCED OR METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA ( Principal Investigator(PI))
  2. 2017 - 2021, Roche (M) Sdn. Bhd.
    A Phase 3, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Abti-PD-L1 Antibody) As Monotherapy and In Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma ( Principal Investigator(PI))
International
  1. 2023 - 2026, Japan Study Group of Prostate Cancer
    Research concerning Background Factors at Time of Diagnosis and Initial Treatment and Treatment Progress of Prostate Cancer Patients: Asia Multi-institution Joint Study (Asia Study Group of Prostate Cancer; A-CaP Study) ( Co-Researcher)
  2. 2010 - 2026, NCC Singapore
    ASCOLT Aspirin in treating patients with Dukes stage C colon or rectal cancer, or high risk Dukes stage B colon cancer that has been completely removed by surgery. ( Consultant)
  3. 2020 - 2024, Johnson & Johnson
    PREVALENCE : A biomarker study to determine frequency of DNA-repair defects in men with metastatic prostate cancer. ( Principal Investigator(PI))
  4. 2020 - 2023, Merck Sharp & Dohme (M) Sdn. Bhd
    KEYNOTE-992 : A Phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy (CRT) versus CRT alone in muscle-invasive bladder cancer. KEYNOTE-992 ( Principal Investigator(PI))
  5. 2019 - 2022, Johnson&Johnson
    MAGNITUDE Study : A phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisolone versus abiraterone acetate and prednisolone for treatment of subjects with metastatic prostate cancer. ( Principal Investigator(PI))
  6. 2013 - 2021, Janssen Research & Development, LLC
    A Randomized, Double-blind, Comparative Study of ZYTIGA (Abiraterone Acetate) Plus Low-dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) ( Principal Investigator(PI))
  7. 2015 - 2020, Industry
    KEYNOTE-052 : A Phase 2 Clinical Trial of Pembrolizumab in Subjects with advanced/ unresectable or metastatic urothelial cancer. ( Principal Investigator(PI))
  8. 2017 - 2020, Roche
    IMvigor 130 : Phase III, multicentre, randomised, placebo-controlled study of atezolizumab (anti PD-L1 antibody) as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma. (WO30070 / IMvigor130) ( Principal Investigator(PI))
  9. 2016 - 2019, Private Funding
    AR-V7 Splice variant in Asian patients with castration resistant prostate cancer (CRPC) ( Principal Investigator(PI))
  10. 2012 - 2018, Janssen Cilag
    LATITUDE : A randomised double-blind comparative study of Zytiga (abiraterone acetate) plus low dose prednisolone plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed subjects with high risk metastatic hormone-naive prostate cancer (mHNPC). LATITUDE ( Principal Investigator(PI))
  11. 2013 - 2018, Medivation and Astella
    PROSPER A multinational, Phase 3, Randomized, Double blinde, Placebo controlled, Efficacy and Safety of Enzalutamide in Patient With Nonmetastatic Castration-Resistant Prostate Canncer ( Consultant)
  12. 2014 - 2016, Samsung Bioepis
    A Phase III Randomised, Double-Blind,Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting ( Consultant)
  13. 2014 - 2015, Genetech Inc
    GDC-0068 Study (JAGUAR) A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, An Inhibitor to Akt, In Combination with Fluoropyrimidine plus Oxaliplatin in Patients with Locally Advanced or Mestatatic Gastric or Gastroesophageal Junction Adenocarcinoma ( Consultant)
  14. 2014 - 2015, NUS
    A Prospective Cohort Study of Patients with Malignant Cord Compression ( Consultant)
  15. 2012 - 2014, GENETECH INC
    A Phase II double-blind placebo-controlled randomised study of GDC-0941 or GDC-0980 with fulvestrant versus fulvestrant in metastatic breast cancer patients resistant to aromatase inhibitors. ( Consultant)
  16. 2011 - 2013, Psioxus Therapeutic Limited
    MT-102-2001 : (Myotec Study) A multicentre, randomized, double-blind, placebo- controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non small-cell lung cancer and colorectal cancer. ( Consultant)
  17. 2009 - 2012, Boehringer-Ingelheim
    LUME-Lung 2 An international, multi-centre phase III randomised controlled trial for second line treatment of recurrent, advanced non-small cell lung cancer, comparing pemetrexed + placebo versus pemetrexed + BIBF1120 (a multi-targeted tyrosine kinase inhibitor). ( Consultant)
  18. 2011 - 2012, Sanofi-Aventis
    Multicentre, single-arm, open label, clinical trial intended to provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen and to document safety of cabazitaxel in these patients. ( Principal Investigator(PI))
  19. 2009 - 2011, Pfizer
    2009AG-013736 (Axitinib) as Second Line Therapy for Asian Patients with Metastatic Renal Cell Cancer ( Principal Investigator(PI))
  20. 2009 - 2011, Roche
    ATHENA A phase IV open label study of bevacizumab plus taxane monotherapy or in combination for the first line treatment of patients with locally recurrent or metastatic breast cancer. ( Principal Investigator(PI))
  21. 2008 - 2008, Sanofi-Aventis
    SAVE-ONCO: A multinational, randomized, double- blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous throboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy ( Consultant)

CONSULTANCY PROJECT


  • Johnson&Johnson : Acexclusive2 - Asia Pacific Prostate Cancer Conference, Johnson&Johnson, Trainer
    12 Oct 2021 - 12 Oct 2021 (International)
  • Johnson&Johnson : Southeast Asia Prostate Cancer Core (Pacer) Faculty Meeting., Johnson&Johnson, Consultant
    25 Sep 2021 - 25 Sep 2021 (International)
  • Viatris : Gcsf - Biosimilar Advisory Board Meeting., Viatris, Consultant
    24 Aug 2021 - 24 Aug 2021 (National)
  • Merck : Management of Urothelial Carcinoma & Renal Cell Carcinoma in Malaysia - Advisory Board Meeting, Merck, Consultant
    14 Aug 2021 - 14 Aug 2021 (National)
  • Eisai : Prognostic Risk Classifications and Its Implications in Treatment of Advanced Renal Cell Carcinoma., Eisai, Lead Trainer
    16 Jul 2021 - 16 Jul 2021 (International)
  • Cipla : Roundtable Meeting - Role of Abiraterone in Prostate Cancer Patients., Cipla, Consultant
    10 Jun 2021 - 10 Jun 2021 (National)
  • Johnson&Johnson : Prostate Cancer Advisory Board Meeting., Johnson&Johnson, Consultant
    24 Apr 2021 - 24 Apr 2021 (International)
  • Ipsen : Rcc Training by Medical Expert., Ipsen, Lead Trainer
    30 Mar 2021 - 30 Mar 2021 (National)
  • Bms - Adboard Mrcc Management, Dec 2020., BMS
    01 Dec 2020 - 01 Dec 2020 (National)
  • Msd - Malaysia Rcc Cancer Expert Input Forum, June 2020., MSD
    01 Dec 2020 - 01 Dec 2020 (National)
  • Astra Zeneca - Prostate Cancer Profound Virtual Advisory Board, Sep 2020., Astra Zeneca
    01 Dec 2020 - 01 Dec 2020 (National)
  • Merck, Pfizer - Asia Pacific Adboard On Genitourinary Cancers, 4 June 2020., Private sector
    01 Dec 2020 - 01 Dec 2020 (International)
  • Johnson&Johnson - 4th Southeast Asia Prostate Cancer Core (Pacer) Faculty Meeting, 20 Jun 2020., Johnson&Johnson
    01 Dec 2020 - 01 Dec 2020 (International)
  • Janssen - Prostate Cancer Advisory Board Meeting, Dec 2020., Janssen
    01 Dec 2020 - 01 Dec 2020 (International)
  • Roche : Asia-Pacific Regional Meeting - Together We Maximise Clinical Outcome of Mrcc Patients., Roche
    01 Dec 2018 - 01 Dec 2018 (International)
  • Msd : Pembrolizumab in Advanced Urothelial Carcinoma, Jan 2018, Kuala Lumpur., MSD
    01 Oct 2018 - 01 Oct 2018 (National)
  • J&J : Advanced Prostate Cancer Treatment Approaches, Oct 2018, Hanoi., J&J
    01 Oct 2018 - 01 Oct 2018 (International)
  • Astellas : Advanced Prostate Cancer Management, Internal Training, May 2018, Kuala Lumpur., Astellas
    01 Oct 2018 - 01 Oct 2018 (National)
  • Novartis : Mrcc Side Effect Management of Targeted Therapy, Internal Training, Jul 2018, Kuala Lumpur., Novartis
    01 Oct 2018 - 01 Oct 2018 (National)
  • Asian Sarcoma Consortium 2nd Meeting, ASC
    01 Jan 2016 - 01 Jan 2018 (International)
  • Novartis : Ribociclib Advisory Board Meeting 7 Dec 2017, Malaysia., Novartis
    01 Dec 2017 - 01 Dec 2017 (National)
  • Eisai : Advisory Board Meeting for Lenvatinib in Advanced Renal Cell Cancer 19 Mar 2017, Taiwan., Eisai
    01 Dec 2017 - 01 Dec 2017 (International)
  • Msd : Malaysian Genitourinary Cancer Advisory Board Meeting 28 Oct 2017, Malaysia., MSD
    01 Dec 2017 - 01 Dec 2017 (International)
  • J&J : Ace 6 Steering Committee Meeting, 10 Mar 2017, Malaysia., J&J
    01 Dec 2017 - 01 Dec 2017 (International)
  • Roche : Malaysian Urothelial Carcinoma Advisory Board Meeting 25 Feb 2017, Malaysia., Roche
    01 Dec 2017 - 01 Dec 2017 (National)
  • Eisai : Renal Cell Carcinoma, Escon 2017 - 18 Mar 2017, Taiwan., Eisai
    01 Dec 2017 - 01 Dec 2017 (International)
  • J&J : Treatment of Advanced Prostate Cancer : Putting Evidence Into Clinical Practice, 2016, Johnson&Johnson
    01 Dec 2016 - 01 Dec 2016 (National)
  • Renal Cell Carcinoma Adboard Meeting, Pfizer
    01 Jan 2016 - 01 Jan 2016 (International)
  • Soft Tissue Sarcoma Advisory Board Meeting, Eisai
    01 Jan 2016 - 01 Jan 2016 (International)
  • Asian Gastric Cancer Expert Meeting, Eli Lilly
    01 Jan 2016 - 01 Jan 2016 (International)
  • Asia-Pacific Bladder Cancer Expert Froum, MSD
    01 Jan 2016 - 01 Jan 2016 (International)
  • Laser Rcc - Case Study On Sunitinib First Line, Pfizer Oncology
    01 Jan 2016 - 01 Jan 2016 (National)
  • Bayer : Prostate Cancer Adboard Meeting - Optimising Treatment for Prostate Cancer, Singapore., Bayer
    01 Dec 2015 - 01 Dec 2015 (International)
  • Pfizer : Rcc Advisory Board - Optimal Management of Renal Cell Carcinoma, Singapore., Pfizer
    01 Dec 2015 - 01 Dec 2015 (International)
  • Johnson&Johnson : 23rd Asia Pacific Cancer Conference Apcc 2015 - Heterogeneity of Prostate Cancer a Guide to Treatment Choice, Indonesia., Johnson&Johnson
    01 Dec 2015 - 01 Dec 2015 (International)
  • Astellas : Prostate Cancer Advisory Board Meeting, Singapore., Astellas
    01 Dec 2015 - 01 Dec 2015 (International)
  • Johnson&Johnson : First Pros-Ova Malignancies Standalone Meeting., Johnson&Johnson
    01 Dec 2015 - 01 Dec 2015 (National)
  • Janssen : Treatment of Metastatic Prostate Cancer - Newer Options. Brunei Cancer Symposium Feb 2015., Janssen
    01 Dec 2015 - 01 Dec 2015 (International)
  • Johnson&Johnson : Prostate Cancer Seminar - Past Present & Future of Treatment, Johnson&Johnson
    01 Dec 2015 - 01 Dec 2015 (National)
  • Sanofi : Prostate Cancer Adboard - Accomplishment & Challenges in Prostate Cancer, Singapore., Sanofi
    01 Dec 2015 - 01 Dec 2015 (International)
  • Roche : Capecitabine Preceptorship for Myanmar Oncologists April 2015., Roche Myanmar
    01 Jun 2015 - 01 Jun 2015 (International)
  • Roche : Chemotherapy Training for Myanmar Nurses Apr 2015, Roche Myanmar
    01 Jun 2015 - 01 Jun 2015 (International)
  • Radiotherapy and Oncology Department Plan for Health Metropolis Project., Health Metropolis
    01 Jan 2010 - 01 Jan 2015 (National)
  • Bayer Adboard : Xofigo Adboard Meeting Apr 2014, Bayer
    01 Nov 2014 - 01 Nov 2014 (International)
  • Astella Adboard : Metastatic Castrate Resistant Prostate Cancer Expert Panel Meeting, Astella
    01 Nov 2014 - 01 Nov 2014 (International)
  • Eisai : Aos Apr 2014 : Metastatic Breast Cancer : What Can We Do Today for Patients? Professor Michael Gnant, Vienna., Eisai
    01 Nov 2014 - 01 Nov 2014 (International)
  • Sanofi : Asia Pacific Genitourinary Conference 2014, Sanofi
    01 Nov 2014 - 01 Nov 2014 (National)
  • Gsk : Aos Apr 2014 : Preventing Sres in Practice : How Early is Early in Patients With Bone Metatstases? Professor Roger Von Moos, Switzerland., GSK
    01 Nov 2014 - 01 Nov 2014 (International)
  • Sanofi : Surf Meeting Jun 2014 : Prostate Cancer Plenary : Role of Chemotherapy & Optimal Sequencing of Therapy., Sanofi
    01 Nov 2014 - 01 Nov 2014 (National)
  • Pfizer : Surf Meeting Jun 2014 : Renal Cancer Plenary : Evolution of Front Line Targeted Therapy & Management of Side Effects - a Survival Guide for Urologists., Pfizer
    01 Nov 2014 - 01 Nov 2014 (International)
  • MARA : Cancer - The Smart Enemy. Decoding Their Strategies in Order to Win The Cancer Battlefield. Biology At Its Molecular Level. Mrsm Biology Teachers Education Summit 2014, 19 May 2014 to 22 May 2014., MARA Excellent Ventures Sdn Bhd
    01 Nov 2014 - 01 Nov 2014 (National)
  • Sanofi : Surf Meeting Jun 2014 : Prostate Cancer Plenary : Role of Chemotherapy & Optimal Sequencing in McRpc., Sanofi
    01 Nov 2014 - 01 Nov 2014 (International)
  • Pfizer Cme Apr 2014 Institut Kanser Negara : a New Second Line Treatment for Mrcc. What Does The Evidence Say?, Pfizer
    01 Aug 2014 - 01 Aug 2014 (National)
  • Pfizer Cme May 2014 Hospital Kuala Lumpur : a New Second Line Treatment for Mrcc. What Does The Evidence Say?, Pfizer
    01 Aug 2014 - 01 Aug 2014 (National)
  • Janssen Cme : Clinical Conversations in McRpc. Professor Charles Ryan, San Francisco., Janssen
    01 Jun 2014 - 01 Jun 2014 (National)
  • Kidney Cancer and Its Treatment Development, Pfizer
    01 Jun 2014 - 01 Jun 2014 (National)
  • Moh : Committee for Revision of National Chemotherapy Protocol Guidelines, Ministry of Health Malaysia
    01 Jun 2014 - 01 Jun 2014 (National)
  • Sanofi : Management of Castrate Resistant Prostate Cancer, Sanofi Oncology
    01 Nov 2013 - 01 Nov 2013 (National)
  • Pfizer : Pow-Wow Rcc Symposium, Pfizer Oncology
    01 Nov 2013 - 01 Nov 2013 (National)
  • Pfizer Adboard : Continuum of Care Expert Panel - Asia Renal Cell Carcinoma Advisory Board Meeting, Pfizer Oncology
    01 Nov 2013 - 01 Nov 2013 (International)
  • Eisai : Beyond Conventional Treatment in Pre-Treated Metastatic Breast Cancer, Eisai
    01 Nov 2013 - 01 Nov 2013 (International)
  • Sanofi : Asia Pacific Genito-Urinary Conference 2013, Sanofi Oncology
    01 Nov 2013 - 01 Nov 2013 (International)
  • South East Asia Radiation Oncology Group (Searog)., SEAROG
    01 May 2011 - 01 May 2013 (International)
  • Davos : Gamma-Delta Tocotrienol : Phase One Dose Escalation and Pharmacokinetics Study On Castrate Resistant Prostate Cancer Patients, Davos Life Science Pte Ltd
    01 Nov 2012 - 01 Nov 2012 (National)
  • Janssen Adboard : Treatment of Prostate Cancer Adboard Meeting, Janssen
    01 Nov 2012 - 01 Nov 2012 (National)
  • Janssen : Training On New Product Abiraterone and Treatment of Metastatic Castrate Resistant Prostate Cancer., Janssen
    01 Nov 2012 - 01 Nov 2012 (National)
  • Moh : National Cancer Patient Registry (Ncpr) : a Patient Registry (Clinical Database) to Evaluate The Health Outcomes of Patients Undergoing Treatment for Cancers in Malaysia., Ministry of Health Malaysia
    01 Nov 2009 - 01 Nov 2012 (National)
  • Sanofi : Jevtana Media Launch - Treatment Paradigm Change for Castrate Resistant Prostate Cancer After Docetaxel Failure, Sanofi Aventis
    01 Nov 2012 - 01 Nov 2012 (National)
  • Pfizer : Hepatocellular Carcinoma and Gastric Cancer Adboard Meeting April 2012, Pfizer Oncology
    01 Nov 2012 - 01 Nov 2012 (International)
  • Medical Nutrition Therapy for Cancer Patients., Malaysian Dietitian Association
    01 May 2011 - 01 May 2012 (National)
  • UPM : Patient Information Article On Cervical Cancer for Cancer Resource and Education Center (Care) UPM., University Putra Malaysia
    01 Nov 2011 - 01 Nov 2011 (National)
  • Gsk Adboard : Her2+ Hr+ Metastatic Breast Cancer Board Meeting 2011., GSK Oncology
    01 Nov 2011 - 01 Nov 2011 (National)
  • Mos : Asian Pacific Cancer Conference, Kuala Lumpur 2011., Malaysian Oncological Society
    01 Nov 2010 - 01 Nov 2011 (International)
  • Mos : Prostate Cancer Symposium, Asia Pacific Cancer Conference 2011., Malaysian Oncological Society
    01 Nov 2011 - 01 Nov 2011 (International)
  • Novartis Adboard : Mtor Inhibitors in Metastatic Renal Cell Carcinoma., Novartis Oncology
    01 Nov 2010 - 01 Nov 2010 (National)
  • Moh : Guidelines for Management of Brachytherapy for Prostate Cancer Using Permanently Implanted Radioactive Sources 2010., Bahagian Perkhidmatan Kejuruteraan
    01 Nov 2010 - 01 Nov 2010 (National)
  • Moh : Workshop On Systemic Therapy of Cancer Protocol for Malaysia, Kementerian Kesihatan Malaysia
    01 Nov 2007 - 01 Nov 2007 (National)

PAPER PRESENTED


CONFERENCE
  1. Shared Decision-Making in Oncology., ECOU 2018 (East Coast Oncology Update), Hospital USM (National) (03 Oct 2018 - 04 Oct 2018)
  2. Practical Management of Immune-Mediated Adverse Events - Immunotherapy Pre-Congress Workshop., 52nd Malaysia-Singapore Congress of Medicine, Academy of Medicine Malaysia, Malaysia Oncological Society (International) (26 Jul 2018 - 26 Jul 2018)
PLENARY SPEAKER
  1. Clinical Trials in Oncology Setting: An Overview, Hospital Aseptic Dispensing Congress 2024, UMMC (National) (17 May 2024 - 19 May 2024)
  2. Maximising Outcomes in High-Risk Muscle-Invasive Urothelial Carcinoma, - HKSUO Annual Scientific Meeting - Uro-Oncology Asia 2024, HKSUO (Hong Kong Society of Uro-Oncology) (International) (13 Jan 2024 - 14 Jan 2024)
  3. Findings from MyPCC 2023, MDT PACMAN, J&J (National) (10 Oct 2023 - 10 Oct 2023)
  4. Prostate Cancer Case Based Discussion, JANSSEN SEA ONCOLOGY SUMMIT 2023 GU CANCER MASTERCLASS SESSION 2 : PROSTATE CANCER, Janssen (International) (23 Sep 2023 - 23 Sep 2023)
  5. PARP Inhibitor And Experimental Treatments For MCRPC, 10th Anniversary of IKN, IKN (National) (19 Sep 2023 - 21 Sep 2023)
  6. Communicating the Value of Precision Medicine to Patient, JANSSEN SEA ONCOLOGY SUMMIT 2023 - PRECISION MEDICINE IN ONCOLOGY: PAVING THE WAY OF PRECISION MEDICINE, Janssen (International) (10 Aug 2023 - 10 Aug 2023)
  7. Metastatic Bladder Cancer - New Advances, 3rd National Oncology Pharmacy Conference 2023, IKN (National) (15 Mar 2023 - 17 Mar 2023)
  8. Intraoperative radiotherapy for breast cancer : Issues and challenges, Weekly webinar on clinical knowledge related to radiation safety, University Malaya Medical Centre (UMMC) (National) (02 Apr 2021 - 30 Apr 2021)
  9. Evolving Treatment Landscape in Advanced/Metastatic Urothelial Carcinoma : Where Are We Now and Where We Hope to Go?, MUC 2017, 26 Nov 2017, Kuching MALAYSIA., 26th Malaysian Urological Conference 2017., MUA (International) (26 Nov 2017 - 26 Nov 2017)
  10. Past Present and Future of Prostate Cancer Treatment, Prostate Cancer Seminar , Johnson&Johnson (National) (13 Jun 2015 - 13 Jun 2015)
  11. Prostate Cancer : Follow-Up After Hormonal Therapy and Determining Recurrence., Asia-Pacific Genito-Urinary Oncology Conference, Hong Kong., Sanofi Oncology (International) (19 Jul 2014 - 20 Jul 2014)
  12. Evolution of Front Line Targeted Therapy in Metastatic Renal Cancer., Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, MUA-SUO (International) (07 Jun 2014 - 08 Jun 2014)
  13. Monitoring and Managing Adverse Events of Targeted Therapy : A Survival Guide for Urologists., Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, MUA-SUO (International) (07 Jun 2014 - 08 Jun 2014)
  14. Optimal Sequencing of Therapy in Castrate Resistant Prostate Cancer, Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, MUA-SUO (International) (07 Jun 2014 - 08 Jun 2014)
  15. Role of Chemotherapy in Castrate Resistant Prostate Cancer, Section of Uro-Oncology Forum : So Many Drugs So Little Time - Prescribing for Uro-Oncology 2014, MUA-SUO (International) (07 Jun 2014 - 08 Jun 2014)
  16. Prostate Cancer : Current Practise and Future Direction, Philippine Society of Medical Oncology Convention, Manila, PSMO Manila, Janssen (International) (16 Oct 2013 - 17 Oct 2013)
  17. Improving Quality of Life : Treatment That Makes a Difference., Asia Pacific Genitourinary Conference, Bangkok, Sanofi Oncology (International) (13 Jul 2013 - 14 Jul 2013)
  18. Sarcoma : a puzzle, maze of labyrinth?, College of Radiology Annual Meeting, Kuala Lumpur, Academy of Medicine, Malaysia Oncological Society (National) (14 Jun 2013 - 14 Jun 2013)
INVITED SEMINAR
  1. Medical Updates on Prostate Cancer & Importance of MDT, Southern Uro-Onco Focus-Group Meeting, Johnson&Johnson (National) (16 Oct 2019 - 16 Oct 2019)
  2. Optimizing Patient Outcome and Improving Overall Survival in First line mRCC Patients - IKN 28th Aug 2019, UKMMC 11th Sep 2019, HATTM 9th Oct 2019, HSI JB 16th Oct 2019, HPP 18th Oct 2019, HKL 18th Nov 2019, UMMC 28th Dec 2019., SUPERDOT : Sharing Sutent Experience if Dose Optimisation - Speaker Tour, Pfizer (National) (28 Aug 2019 - 28 Nov 2019)
  3. New Approaches in the Treatment of Advanced Prostate Cancer, Hanoi., Treatment of Advanced Prostate Cancer, Johnson&Johnson (International) (07 Oct 2018 - 07 Oct 2018)
  4. 1. Resource-Stratified Practice in Advanced Prostate Cancer Management, 2. Bone-Modulating Agents.in Treatment of Metastatic Prostate Cancer., ESMO Advanced Course on Clinical Question in Prostate Cancer, ESMO, SSO (International) (21 Sep 2018 - 22 Sep 2018)
  5. Advanced Prostate Cancer Management Across Asia - Malaysian Experience., Asia Prostate Cancer Experts Meeting, Sanofi (International) (20 Sep 2018 - 20 Sep 2018)
  6. 1. Optimizing Patient Outcome and Improving Overall Survival in 1st Line mRCC, 2. Optimizing the Continuum of Care for mRCC Patients., SUPERDOT (Sharing Sunitinib Experience in Dose Optimisation) (Seminar), Pfizer (National) (07 Sep 2018 - 07 Sep 2018)
  7. Optimizing Patient Outcome and Improving Overall Survival in 1st Line mRCC., SUPERDOT (Sharing Sunitinib Experience in Dose Optimisation), Pfizer (National) (06 Sep 2018 - 06 Sep 2018)
  8. Updates on Management of Prostate Cancer., Sabah Uro-Onco Focus Group Discussion., Johnson&Johnson (National) (06 Sep 2018 - 06 Sep 2018)
  9. Optimizing Patient Outcome and Improving Overall Survival in 1st Line mRCC, SUPERDOT (Sharing Sunitinib Experience in Dose Optimisation) (Seminar) (Seminar), Pfizer (National) (09 Aug 2018 - 09 Aug 2018)
  10. Evolving and Emerging Roles of Immunothherapy in Renal and Urothelial Cancers., Immuno-Oncology : New in Cancer Treatment (ICONIC), Astra-Zeneca (National) (11 Mar 2018 - 11 Mar 2018)
  11. mRCC Optimal Treatment Case Presentation, Leadership & Scientific Exchange Regional Series : Renal Cell Carcinoma, Pfizer (International) (18 May 2016 - 18 May 2016)
  12. Panel Discussion on Adverse Event Management, POW WOW RCC Symposium, Pfizer (National) (20 Apr 2013 - 21 Apr 2013)
INVITED SPEAKER
  1. Invited Discussant for GU Mini Oral, ESMO Asia 2023, ESMO (International) (01 Dec 2023 - 03 Dec 2023)
  2. Transition from mCSPC to mCRPC - Case Presentation, ESMO Asia 2023, ESMO (International) (01 Dec 2023 - 03 Dec 2023)
  3. Current challenges and management of prostate cancer - local perspectives, ONCOTalk, Dr Reddy's (National) (28 Oct 2023 - 28 Dec 2023)
  4. Radiotherapy in Metastatic Prostate Cancer, ASCOMOS 2023, Malaysia Oncology Society (International) (06 Oct 2023 - 08 Oct 2023)
  5. Urothelial carcinoma - Overview of management in Malaysia, Lunch CME, Astellas (National) (09 Aug 2023 - 09 Aug 2023)
  6. Immunotherapy & Pathway Modulator - CDK4/6 and PARP Inhibitors, MSCT 2023, Department of Clinical Oncology, UMMC (National) (15 Jul 2023 - 16 Jul 2023)
  7. Highlights of ESMO 2022 and ESMO Asia 2022, MDT PACMAN - Best of 2022, Johnson&Johnson (National) (10 Dec 2022 - 10 Dec 2022)
  8. How can we further optimise the management of patients with advanced renal cancers, ESMO Asia Congress 2022, European Society for Medical Oncology (International) (02 Dec 2022 - 02 Dec 2022)
  9. Beyond surgery and applying multidisciplinary approach - Updates on medical management of advanced prostate cancer, Makati Medical Centre Postgraduate Course, Makati Medical Centre Manila (International) (14 Nov 2022 - 15 Nov 2022)
  10. Systemic therapy for prostate cancer, Experience exchange with Chiba, Johnson&Johnson (International) (04 Aug 2022 - 04 Aug 2022)
  11. Pharmacology of PARP inhibitors, Masterclass in systemic cancer therapy, Clinical Oncology UMMC (National) (30 Jul 2022 - 31 Jul 2022)
  12. Updated overall survival outcomes in ENZAMET (ANZUP 1304),an international, cooperative group trial of enzalutamide inmetastatic hormone-sensitive prostate cancer (mHSPC)., Best of ASCO (BASCO) Malaysia, MOS, ASCO (International) (23 Jul 2022 - 24 Jul 2022)
  13. Overview of postgraduate training in clinical-based disciplines in Malaysia, Train the Trainers - NPMC Clinical Oncology, NPMC Clinical Oncology  (National) (01 Jul 2022 - 21 Aug 2022)
  14. Case study : Encompassing the two controversies, MDT-PACMAN : National Expert Meeting, Johnson&Johnson (National) (10 Dec 2021 - 10 Dec 2021)
  15. Erleada - Is skin rash really a concern?, Project PROSPECT, Johnson&Johnson (International) (08 Dec 2021 - 08 Dec 2021)
  16. A Case of Upper Tract Urothelial Carcinoma, ESMO Asia - Urothelial Cancer Preceptorship, European Society of Medical Oncology (ESMO), Singapore Society of Oncology (SSO) (International) (17 Nov 2021 - 18 Nov 2021)
  17. The urgency to treat early and the evolving landscape of prostate cancer treatment., MDT PACMAN Digital Forum - Borneo Edition., Johnson & Johnson (National) (21 Aug 2020 - 21 Aug 2020)
  18. Malaysia experience of apalutamide in prostate cancer. , PACMAN National Expert Meeting., Johnson & Johnson (National) (15 Jun 2020 - 15 Jun 2020)
  19. 1. The evolving standard in mCSPC and its practical implications 2. Novel Imaging - Do We Need to Catch Them All?, MDT-PacMan (Multidisciplinary Team in Prostate Cancer Management) - Shifting the Treatment Paradigm of Prostate Cancer Earlier, Johnson&Johnson (National) (30 Nov 2019 - 30 Nov 2019)
  20. Extreme Hypodfractionation - Early Results, 4th Federation of Asian Organisations for Radiation Oncology (FARO), FARO (International) (13 Nov 2019 - 16 Nov 2019)
  21. Renal And Urologic Malignancies : Oncological Management Of RCC: New Targeted Drugs & Outcome, 6th Asia Pacific Congress in Interventional Oncology 2019 (APCIO), APCIO (International) (03 Oct 2019 - 05 Oct 2019)
  22. mCSPC - Optimal Systemic Treatment in Current Era, MOS-Amgen Oncology Meeting, Amgen, MOS (National) (07 Sep 2019 - 07 Sep 2019)
  23. Comprehensive Management of Prostate Cancer, Management of Prostate Cancer, Johnson&Johnson (International) (27 Jun 2019 - 27 Jun 2019)
  24. An Update of Advanced Prostate Cancer Management, Management of Prostate Cancer, Johnson&Johnson (International) (26 Jun 2019 - 26 Jun 2019)
  25. 1. Subsequent Line of Systemic Therapy 2. Side Effects Management of Targeted Therapy 3. Case Discussion, Renal Cancer Preceptorship (RECAP 2.0), UM, MUA, MOS (National) (02 May 2019 - 03 May 2019)
  26. The Need for Multidisciplinary Team., MDT PaCMan 1.0. The Multidisciplinary Team in Prostate Cancer Management, Johnson&Johnson (National) (06 Apr 2019 - 06 Apr 2019)
  27. Role of chemotherapy & radiotherapy in cancerous wounds and stoma., Malaysian Enterostomal Therapy Nursing Education Program (Malaysian ETNEP), UMMC (International) (13 Mar 2019 - 13 Mar 2019)
  28. Choosing the Most Optimal Treatment Regimen in mHSPC., 1st South East Asia Prostate Cancer Centre of Excellence., Johnson&Johnson, Singapore Society of Oncology, Singapore Urological Association (International) (17 Aug 2018 - 18 Aug 2018)
  29. Treatment Sequencing in mCRPC., 1st South East Asia Prostate Cancer Centre of Excellence., Johnson&Johnson, Singapore Society of Oncology, Singapore Urological Association (International) (17 Aug 2018 - 18 Aug 2018)
  30. Metastatic Castrate Sensitive Prostate Cancer, MEN United V3.0, Astellas (National) (11 Aug 2018 - 11 Aug 2018)
  31. 1. Neoadjuvant and Adjuvant Treatment Soft Tissue Sarcoma, 2. Multidisciplinary Management Sarcoma 3. mHSPC What is the Best Treatment Modality?, Johor Oncology Meeting (JOM), Hospital Sultan Ismail JB (National) (09 Aug 2018 - 11 Aug 2018)
  32. 1. Optimising Care in mCRPC, 2. Current Standard of Care and New Advances in mCSPC., Optimising Care in Advanced Prostate Cancer, Johnson&Johnson (National) (05 Apr 2018 - 05 Apr 2018)
  33. 1. Principles of Cancer Therapy, 2. Future of Cancer Therapy., Oncology Colloquium., Malaysian Medics International (International) (02 Feb 2018 - 03 Feb 2018)
  34. Finding the Magic Bullet - Managing mCNPC in 2017 : A Paradigm Shift? MUC 2017, 26 Nov 2017, Kuching MALAYSIA., 26th Malaysian Urological Conference., MUA (International) (25 Nov 2017 - 25 Nov 2017)
  35. ESMO Asia Colloquium - Selection Criteria for mCRPC : Bone Targeting Agents, ESMO Asia 2017, 18 Nov 2017, SINGAPORE., ESMO Asia 2017., ESMO, SSO (International) (17 Nov 2017 - 19 Nov 2017)
  36. (1) Changing Treatment Landscape of Advanced Prostate Cancer : Current Standard of Care and New Advances. (2) LATITUDE Experience., Brunei Uro-Onco Focus Group Discussion., Johnson&Johnson (International) (04 Nov 2017 - 04 Nov 2017)
  37. (1) Advanced Prostate Cancer Highlights from ASCO & ESMO. (2) LATITUDE Insights from LATITUDE Trial Investigator., Advanced Prostate Cancer Workshop., Johnson&Johnson (International) (30 Sep 2017 - 01 Oct 2017)
  38. LATITUDE Experience, Rethinking Treatment of Metastatic Prostate Cancer, 19 Sep 2017, SINGAPORE., Rethinking Treatment of Metastatic Prostate Cancer : Insights Sharing Session., Johnson&Johnson. (International) (19 Sep 2017 - 19 Sep 2017)
  39. mRCC : Role of Targeted Therapy Beyond First Line., Precision Medicine., IKN. (National) (04 Sep 2017 - 06 Sep 2017)
  40. The Science and Treatment Options of CRPC in Malaysia., Meet the Expert Session., Bayer (International) (19 Aug 2017 - 19 Aug 2017)
  41. Renal Cell Carcinoma : Determining Therapeutic Strategy after Disease Progression., PROMISE (PfizeR Oncology Meeting Integrating Science Evidences into clinical practice)., Pfizer Oncology. (National) (05 Aug 2017 - 05 Aug 2017)
  42. Management of Early and Advanced Stage Germ Cell Tumour, JOM 2017, 3 Mar 2017, Johor Bahru MALAYSIA., Johor Oncology Meeting., Oncology Department, Hospital Sultan Ismail, Johor Bahru. (National) (03 Aug 2017 - 05 Aug 2017)
  43. Overview of Adjuvant Radiation Therapy in Soft Tissue Sarcoma, Sarcoma Preceptorship, 17 Jul 2017, SINGAPORE., Sarcoma Preceptorship., Asian Sarcoma Consortium. (International) (14 Jul 2017 - 15 Jul 2017)
  44. Overview of Current Clinical Trials in mHSPC., Southeast Asia Prostate Cancer Core Faculty Meeting (PACER)., Johnson&Johnson (International) (06 May 2017 - 06 May 2017)
  45. (1) Novel Agents in Advanced Prostate Cancer : Monitoring Parameters and Safety Profiles. (2) Managing Complications of Chemotherapy., Oncology Pharmacists and Nurses Seminar : Prostate Cancer & Pain Management., Johnson&Johnson (National) (22 Apr 2017 - 22 Apr 2017)
  46. Intraoperative Radiotherapy - A New Technique in Malaysia., Breast Cancer Public Forum, UMMC (National) (09 Oct 2016 - 09 Oct 2016)
  47. Prostate Cancer After Preliminary Treatment : What Next?, Together Let's Fight Prostate Cance, Prostate Cancer Support Group (National) (01 Oct 2016 - 01 Oct 2016)
  48. Metastatic Prostate Cancer : What are The Options?, Together Let's Fight Prostate Cancer, Prostate Cancer Support Group (National) (01 Oct 2016 - 01 Oct 2016)
  49. Management of Metastatic Castrate Resistant Prostate Cancer, Focus Group Meeting, Johnson&Johnson (National) (01 Oct 2016 - 01 Oct 2016)
  50. Optimal Sequencing in mCRPC, Management of Castrate Resistant Prostate Cancer, Johnson&Johnson (National) (30 Sep 2016 - 30 Sep 2016)
  51. Shared Decision Making, Onco-Lead Workshop 2016, Dept of Clinical Oncology UMMC (National) (20 Aug 2016 - 20 Aug 2016)
  52. Chemotherapy & Targeted Therapy in Soft Tissue Sarcoma : Can We Improve Outcome Further?, 46th Malaysian Orthopaedic Association Annual Scientific Meeting, MOA (International) (27 May 2016 - 27 May 2016)
  53. Chemotherapy and Targeted Therapy in Soft Tissue Sarcoma : Can We Improve Survival?, 46th Malaysian Orthpaedic Association Annual Scientific, MOA (International) (25 May 2016 - 28 May 2016)
  54. Optimising Care in Metastatic Renal Cancer - Case Discussion., Leadership and Scientific Exchange Regional Series (LASERS), Pfizer Oncology (International) (18 May 2016 - 18 May 2016)
  55. Shared Decision Making, Pre-Congress Workshop College of Surgeon Annual Scientific Meeting - Masterclass in Communication, College of Surgeons Malaysia (International) (11 May 2016 - 11 May 2016)
  56. Oncological Treatment : To Give or Not To Give? That is the Question., Malaysian Hospice Congress, Malaysian Hospice Council (International) (22 Apr 2016 - 24 Apr 2016)
  57. Role of Chemotherapy & Radiotherapy in Cancer and Cancer-related Stoma., Enterostomal Therapy Nursing Education Programme 2016, UMMC (National) (24 Mar 2016 - 24 Mar 2016)
  58. Sarcoma : Targeted Therapy and Survival, Orthopaedic Oncology and Reconstructive Course, Universiti Sains Malaysia (National) (26 Aug 2015 - 27 Aug 2015)
  59. Heterogeneity of Prostate Cancer : Guide to Treatment Choice., The 23rd Asia Pacific Cancer Conference (APCC) 2015 : Cancer Care for All - From Prevention to Palliation., Indonesian Society of Oncology, APFOC, UICC (International) (20 Aug 2015 - 22 Aug 2015)
  60. Current Trend in Oncology Management and Survival., 45th Malaysian Orthopaedic Association Annual Scientific Meeting 2015 : Current Trend and the Future in Orthopaedics., Malaysian Orthopaedic Association (International) (22 May 2015 - 24 May 2015)
  61. Breast Cancer : Conventional Treatment, Recurrence and Metastasis, Reach to Recovery : A training workshop for breast cancer survivors, Candy Girls UMMC (National) (09 May 2015 - 09 May 2015)
  62. Planning and Managing Toxicities of Xeloda Treatment., Xeloda Preceptoship 3rd for Myanmar Oncologists, UMMC & Roche Myanmar (International) (13 Apr 2015 - 15 Apr 2015)
  63. Oral Chemotherapy, Xeloda Preceptorship 4th for Myanmar Nurses, UMMC & Roche Myanmar (International) (06 Apr 2015 - 08 Apr 2015)
  64. Role of Radiotherapy and Chemotherapy in Cancerous Wounds and Stoma., Malaysian Enterostomal Therapy Nursing Educational Programme (Malaysian ETNEP), University Malaya Medical Centre (International) (19 Mar 2015 - 19 Mar 2015)
  65. Radiotherapy Contouring for Prostate Cancer , Radiotherapy Contouring Course, Universiti Kebangsaan Malaysia Medical Centre, University Malaya Medical Centre (National) (27 Feb 2015 - 27 Feb 2015)
  66. Treatment of Metastatic Prostate Cancer - Newer Options., The Brunei Cancer Centre Prostate Cancer Symposium, The Brunei Cancer Centre, Johnson & Johnson (International) (14 Feb 2015 - 15 Feb 2015)
  67. Treatment of Metastatic Prostate Cancer : Recent Updates., ESMO-MOS Conference 2015, Malaysian Oncology Society, European Society of Medical Oncology (International) (23 Jan 2015 - 25 Jan 2015)
  68. Why Do I Need Chemotherapy - Factors that Affect Outcome., The First UMMC Breast Cancer Public Forum, Breast Cancer Resource Center UMMC (National) (18 Oct 2014 - 18 Oct 2014)
  69. Principles of Radiotherapy and Chemotherapy in Sarcoma, Orthopaedic Oncology Intensive Course 2014, Orthopaedic Department, UM (University) (11 Oct 2014 - 11 Oct 2014)
  70. Expanding Treatment Options in mRCC and Adverse Event Management, Lunch CME at Hospital Universiti Sains Malaysia, Kubang Kerian, Pfizer Oncology (National) (03 Sep 2014 - 03 Sep 2014)
  71. Cancer : The smart enemy. Decoding their strategies in order to win the cancer battlefield. Biology at its molecular level., MRSM BIOLOGY TEACHERS EDUCATION SUMMIT 2014, MRSM (MARA) (National) (19 May 2014 - 22 May 2014)
  72. A new second line treatment in mRCC : what does the evidence say?, Lunch CME at HKL, Pfizer Oncology (National) (12 May 2014 - 12 May 2014)
  73. A new second line treatment for mRCC : what does the evidence say?, Lunch CME at Institut Kanser Negara, Putrajaya, Pfizer Oncology (National) (30 Apr 2014 - 30 Apr 2014)
  74. Management of Chemotherapy Side Effects, Aseptic Dispensing Course 2013, PENSMA (International) (11 Nov 2013 - 11 Nov 2013)
  75. Management of Castrate Resistant Prostate Cancer, Aseptic Dispensing Course 2013, PENSMA (International) (10 Nov 2013 - 10 Nov 2013)
  76. Tripartite Track : New Frontier in Early Breast Cancer : Hormonal Therapy - What's New?, 2nd AMM-ASM-HKAM Tripartite Congress & 4th Singapore-Malaysia Congress of Medicine, AMM, ASM, HKAM (International) (23 Aug 2013 - 24 Aug 2013)
  77. Clinical Biomarker to Sunitinib Efficacy, POW WOW RCC Symposium, Pfizer Oncology (National) (20 Apr 2013 - 21 Apr 2013)
  78. Timing of surgery and systemic therapy for mRCC, MUA-MOS-SUS Conference 2012, MUA and MOS (International) (23 Nov 2012 - 25 Nov 2012)
  79. Case study on locally advanced prostate cancer, Art of Uro-Oncology, Malaysian Oncology Society, Malaysian Urological Association, Singapore Urological Association (International) (18 Feb 2012 - 19 Feb 2012)
  80. Medical Management of Bone Metastasis, International Metastatic Bone Disease Course, UM (International) (20 May 2011 - 21 May 2011)
  81. mTOR inhibitor : 1 year on. , Oncology Free Standing Symposium 1 Oncology, MOS and Novartis (National) (12 Nov 2010 - 13 Nov 2010)
  82. Improving outcome of patients with bone metastases., Oncology Free Standing Symposium 1 Oncology., MOS Novartis (National) (12 Nov 2010 - 12 Nov 2010)
  83. Systemic Therapy for Cancer, Oncology Nursing Seminar, UM (University) (28 Sep 2010 - 29 Sep 2010)
  84. RCC Case presentation, 1st MOS-MUA Uro-Onccology Meeting : Kidney Cancer Series, MOS, MUA, Pfizer (National) (17 Jul 2010 - 18 Jul 2010)
  85. Molecular targeted therapy in renal cell carcinoma., First MOS-EOF Conference : Hands in hands in Cancer., MOS, MUA, EOF (International) (01 May 2010 - 02 May 2010)
  86. The issues on follow-up and complications of radiotherapy in nasopharyngeal and laryngeal cancers., MOS-MSOHNS Joint Meeting : New Frontier in the Management of Nasopharyngeal and Laryngeal Cancer , MOS-MSOHNS of Malaysia (National) (10 Oct 2009 - 11 Nov 2009)
  87. Adjuvant Breast Cancer : The time to change, Johore Scientific Meeting, KKM (National) (20 Jul 2009 - 22 Jul 2009)
  88. Management of Acute and Late Side-effects of Radiotherapy, Medical Imaging and Radiation Therapy Updates , MSR (National) (25 Jun 2009 - 26 Jun 2009)
  89. Radiotherapy in Gynaecological Cancers : An Overview, Emerging Themes in Gynaecology Oncology The Way Forward, Department of Obstetrics and Gynaecology, University Malaya (National) (15 Aug 2008 - 17 Aug 2008)
  90. New Moves in Breast Cancer : AntiVEGF & AntiHER2 Therapy, Annual Scientific Meeting College of Surgeons : Detecting Cancer Earlier, College of Surgeons  (National) (08 Jun 2007 - 10 Jun 2007)
EVENT ORGANISER
  1. RECAP 2.0, Renal Cancer Preceptorship (RECAP 2.0), UM (National) (02 May 2019 - 03 May 2019)
  2. 1. Prognostic and Predictive Markers in RCC, 2. Subsequent Lines of Treatment, 3. Side Effects Management, 4. Bone Targeting Agents., Renal Cancer Preceptorship, UM, Novartis (International) (03 May 2018 - 04 May 2018)
  3. Pushing the Boundaries of Cancer Together., 29th ASCOMOS., MOS. (International) (08 Dec 2017 - 10 Dec 2017)
  4. Organising Committee : Masterclass in Systemic Anti-Cancer Therapy, Mar 2017, UMMC, KUALA LUMPUR.., MSCT2017., Department of Clinical Oncology UMMC. (National) (04 Mar 2017 - 05 Mar 2017)
  5. S.O.S. Strategise Optimal Solution., Section of Uro-Oncology Forum (SURF)., MUA, MOS (National) (30 Apr 2016 - 30 Apr 2016)
  6. Not applicable., Stereotactic Radiosurgery and Radiotherapy for Cranial Lesions., Department of Clinical Oncology, UMMC (National) (11 May 2015 - 14 May 2015)
  7. Improving Outcome in the Management of Colorectal Cancer, Colorectal Cancer : An MDT Workshop, Department of Clinical Oncology UMMC, Merck Serono (National) (29 Mar 2014 - 29 Mar 2014)
  8. Championing Cancer Care in Malaysia, MOS Annual Scientific Meeting, MOS (International) (29 Nov 2013 - 01 Dec 2013)
  9. Musculoskeletal Imaging, COR Annual Scientific Meeting, COR, MOS, MSR (National) (14 Jun 2013 - 15 Jun 2013)
  10. The Science and Strategy of Cancer Control., 21st Asia Pacific Cancer Conference., Malaysia Oncological Society (International) (10 Nov 2011 - 12 Nov 2011)
ORAL PRESENTER
  1. 258MO - Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): 2nd interim analysis in the Asian subgroup of the MAGNITUDE study, ESMO Asia 2023, ESMO (International) (01 Dec 2023 - 03 Dec 2023)
  2. 158MO - Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study , ESMO Asia Congress, European Society for Medical Oncology (International) (02 Dec 2022 - 04 Dec 2022)
  3. Marniza Saad, Flora Chong Li Tze, Mastura Md Yusof, Anita Bustam, Ho Gwo Fuang, Daniel Wong Wai Yan, Rozita Abdul Malik, Wan Zamaniah Wan Ishak. Prospective Controlled Study on the role of scalp hypothermia to prevent chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy (SHARE study) : Final Analysis. APCC, Oct 2011., Asia Pacific Cancer Conference 2011, Malaysian Oncological Society (International) (10 Nov 2011 - 12 May 2011)
  4. Lau Kah Liew, Ho Gwo Fuang, Lim Chun Sen, Wong Wai Yan, Marniza Saad, Anita Bustam, Christina Ng. Adjuvant epirubicin, cisplatin and capecitabine (ECX) and chemoradiation with concurrent capecitabine for resected gastric cancer. Malaysian Oncological Society Annual Scientific Meeting, October 2009., ASCOMOS 2009, MOS (International) (24 Oct 2009)
  5. The Status of Radiation Oncology and Management of Locally Advanced Cervical Cancer in Malaysia, IAEA/RCA Regional Training Course on the Optimal Management of Locally Advanced Cervical Cancer, IAEA (International) (10 Sep 2007 - 14 Sep 2007)
POSTER PRESENTER
  1. Apalutamide for Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC): A Comparison of Real-Life Experience from an International Named Patient Program (NPP) vs the Prior Phase 3 Clinical Study, ASCOMOS 2021, Malaysian Oncological Society (National) (29 Oct 2021 - 31 Oct 2021)
  2. Efficacy and safety of pazopanib in advanced renal cell carcinoma treated at University Malaya Medical Centre (UMMC)., ASCOMOS 2017, Malaysia Oncological Society (International) (09 Dec 2017 - 09 Dec 2017)
  3. Efficacy & Safety of Pazopanib in Advanced Renal Cell Carcinoma : Review in UMMC., ASCOMOS 2017., MOS (International) (08 Dec 2017 - 10 Dec 2017)
  4. Abiraterone in metastatic castrate resistant prostate cancer: outcome and tolerance in real-world setting., 26th Malaysian Urological Conference, MUA (International) (23 Nov 2017 - 25 Nov 2017)
  5. Diagnostic Dilemma : A Case of Metastatic Tubulocystic Carcinoma of Kidney., ESMO Asia 2016, ESMO, SSO (International) (16 Dec 2016 - 19 Dec 2016)
  6. Treatment Outcome of Metastatic Prostate Cancer Patients Treated at UMMC, ESMO Asia 2016, ESMO, SSO (International) (16 Dec 2016 - 19 Dec 2016)
  7. Treatment outcomes of patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC) on first line docetaxel chemotherapy at University Malaya Medical Centre., Malaysian Urology Conference, MUA (International) (24 Nov 2016 - 26 Nov 2016)
  8. The unusual kid on the block:Primary Renal Ewing Sarcoma, Malaysian Urology Conference, MUA (International) (24 Nov 2016 - 26 Nov 2016)
  9. Real-World experience with abiraterone in metastatic castrate resistant prostate carcinoma in University Malaya Medical Centre., Malaysian Urology Conference, MUA (International) (24 Nov 2016 - 26 Nov 2016)
  10. NK Abd Ghafar, A Alip, TA Ong, M Saad. Efficacy and safety of first line sunitinib in patients with metastatic renal cell cancer: a Malaysian experience from a single tertiary centre. BJU International 2015, 116, Supplement 4, 1-27., 24th Malaysian Urological Association Conference, MUA (International) (20 Nov 2015 - 22 Nov 2015)
  11. J Lim, N Bhoo-Pathy, A Alip, M Saad, TA Ong, AHA Razack. The prostate cancer profile in multiethnic Asian men. BJU International 2015, 116, Supplement 4, 1-27., Malaysia Urology Association Annual Scientific Meeting Oct 2015., MUA (International) (23 Oct 2015 - 25 Oct 2015)
  12. Prognostic Factors in Breast Cancer Patients with Brain Metastases., European Society of Medical Oncology., ESMO (International) (29 Sep 2015 - 03 Oct 2015)
  13. Mastura Md Yusof, Suhana Yusak, Wan Zamaniah Wan Ishak, Rozita Abdul Malik, Adlinda Alip, Vincent Phua Chee Ee, Marniza Saad. Outcome of routine radioiodine ablation for differentiated thyroid cancer in an academic institution in Kuala Lumpur Malaysia., ASCOMOS 2013, MOS (International) (29 Nov 2013 - 01 Dec 2013)
  14. Fiona Lian, Marniza Saad, Imran Zainal Abidin, Mun Kein Seong. Meaningful clinical benefit with weekly paclitaxel in primary cardiac angiosarcoma., ASCOMOS 2013, MOS (International) (29 Nov 2013 - 01 Dec 2013)
  15. Daniel Gan Eng-Hwee, Teh Yew Ching, Marniza Saad, Tan Gie Hooi, Yip Cheng Har, Nur Aishah Taib. Prevalence and outcomes of primary breast sarcoma and malignant Phyllodes tumour in Asian Women., ASCOMOS 2013, MOS (International) (29 Nov 2013 - 01 Dec 2013)
  16. Mastura Md Yusof, Suhana Yusak, Wan Zamaniah Wan Ishak, Rozita Abdul Malik, Adlinda Alip, Vincent Phua Chee Ee, Marniza Saad.Outcome of Routine Radioiodine Ablation for Differentiated Thyroid Cancer in an Academic Institution. APCC Oct 2013. in Kuala Lumpur, Malaysia, 22nd Asia Pacific Cancer Confefence, APCC (International) (31 Oct 2013 - 02 Nov 2013)
  17. Sucharit Pongprakyun, Marniza Saad. Dramatic PSA response with third line chemotherapy in metastatic castrate resistant prostate cancer, Annual Scientific Clinical Oncology Meeting, MOS, Sept 2012., ASCOMOS 2012, MOS (International) (28 Sep 2012)
  18. Marniza Saad, Tang Weng Heng, Marfu'ah Eezamuddeen. Ten year survival in metastatic renal cell carcinoma treated with repeated local treatment and sequential systemic therapy. ACOS, 2012., Asian Clinical Oncology Society Conference, ACOS (International) (13 Jun 2012 - 15 Jun 2012)
  19. Mohd Izuan Ibrahim, Nani Adilah Suhaimi, Nurain Suhairah Mohmad Kassim, Marniza Saad. Entrance Surface Dose of the Contralateral Breast Using Dynamic and Physical Wedges in the Half-Beam and Open-Field Irradiation Techniques. 2nd UKM-SGH Health Sciences Joint Seminar, April 2011., 2nd UKM-SGH Health Sciences Joint Seminar (National) (09 Apr 2011)
  20. Flora Chong Li Tze, Marniza Saad, Nazarina A..R., Lee M.Y. Fibrosarcoma arising within a dermatofibrosarcoma protuberans with lung metastases : a case report. Malaysian Oncology Society Annual Scientific Meeting, October 2010. , MOS Annual Scientific Meeting, MOS (National) (30 Sep 2010 - 03 Oct 2010)
  21. Lau Kah Liew, Marniza Saad, Vivek Ajit Singh. The Outcome of Localised Adult Soft Tissue Sarcoma Treated at University Malaya Medical Centre : Single Institutional Experience, MOS Annual Scientific Meeting, MOS (National) (30 Sep 2010 - 03 Oct 2010)
  22. Marniza Saad, Christina Ng Van Tze. Prolonged Survival with Second Line Everolimus in Metastatic Renal Cell Carcinoma after Failure of Tyrosine Kinase Inhibitor. MOS Annual Scientific Meeting, Sep 2010. , MOS Annual Scientific Meeting, MOS (National) (30 Sep 2010 - 03 Oct 2010)
  23. Marniza Saad, Flora Chong Li Tze, Mastura Md Yusof, Anita Bustam, Ho Gwo Fuang, Daniel Wong Wai Yan, Rozita Abdul Malik, Wan Zamaniah Wan Ishak. Prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy (SHARE study). MOS Annual Scientific Meeting, Sep 2010., MOS Annual Scientific Meeting, Malaysian Oncological Society (National) (30 Sep 2010 - 03 Oct 2010)
  24. Cheah SK, Wong DWY, Marniza S, Anita ZB. Pitfalls in Oncology : Patient with previous buccal mucosa carcinoma presenting with progressive left hemiparesis. Malaysian Oncological Society Annual Scientific Meeting, October 2008., ASCOMOS 2008, MOS (International) (25 Oct 2008)
  25. Rejab M, Wong DWY, Zamzarinah K, Saad M, Bustam A, Ho GF. Computerized versus conventional planning for craniospinal irradiation of medulloblastoma - a dosimetric study. Malaysian Oncology Society Annual Scientific Meeting , Oct 2008., Malaysian Oncological Society Scientific Meeting 2008, MOS (National) (17 Oct 2008 - 19 Oct 2008)
  26. Cheah SK, Wong DWY, Marniza S, Anita ZB. Pitfalls in radiotherapy - re-irradiation for head and neck cancers. MOS Annual Scientific Meeting, Oct 2008., Malaysian Oncological Society Scientific Meeting 2008., Malaysian Oncological Society (National) (16 Oct 2008 - 19 Oct 2008)
PRESENTER
  1. Xeloda in Breast Cancer, Xeloda Preceptorship Programme UMMC March 2014, Department of Clinical Oncology, UMMC (International) (11 Mar 2014 - 15 Mar 2014)
  2. AGILE study results - UMMC case series, Axitinib : new second line treatment for RCC. Department CME., Pfizer Oncology (Others) (05 Mar 2014 - 05 Mar 2014)
KEYNOTE SPEAKER
  1. Prostate Cancer - When can we use PSMA-PET?, SIU Prostate Unlimited 2021, Societe Internationale d'Urologie (SIU) (International) (04 Dec 2021 - 04 Dec 2021)
OTHERS
  1. 1. nmCRPC MDT Case Discussion, 2. Breakout Session - Personalised Treatment Approach, South East Asia - Integrated Multidiciplinary Prostate Cancer Training Workshop (SEA IMPACT), Astellas (International) (09 Nov 2019 - 09 Nov 2019)
  2. Oligometastatic Prostate Cancer., Advanced Prostate Cancer Consensus Conference (APCCC) : Asia-Pacific (APAC) Satellite Symposium., ANZUP (International) (23 Feb 2018 - 23 Feb 2018)
  3. Judge Oral / Poster : Pushing the Boundaries of Cancer Together, ASCOMOS 2017 8-10 Dec 2017, MALAYSIA., 29th ASCOMOS., MOS (International) (08 Dec 2017 - 10 Dec 2017)
  4. Chairperson : ESMO Asia Colloquium - Selection Criteria for TheTreatment of mCRPC, 17-19 Nov 2017, SINGAPORE., ESMO Asia 2017., ESMO, SSO. (International) (17 Nov 2017 - 19 Nov 2017)
  5. Chair : Renal Cell Carcinoma Stream - 22-23 Jul 2017, MALAYSIA.., NOVO Summit 2017., Novartis (International) (22 Jul 2017 - 23 Jul 2017)
  6. Mentor : Multidisciplinary Case Discussion, Sarcoma Preceptorship 14 Jul 2017, SINGAPORE., Sarcoma Preceptorship, Asian Sarcoma Consortium (International) (14 Jul 2017 - 15 Jul 2017)
  7. Chaiperson : ESCON (Eisai Symposium of Contemporary Oncology) - Renal Cell Carcinoma, 18-19 Mar 2017, TAIWAN., ESCON 2017, Eisai (International) (18 Mar 2017 - 19 Mar 2017)
  8. Chairperson : Masterclass in Systemic Anti-Cancer Therapy, Mar 2017, UMMC, KUALA LUMPUR.., MSCT 2017, UMMC, MOS, MOH, UKM (National) (04 Mar 2017 - 05 Mar 2017)
  9. Scientific Committee : Masterclass in Systemic Anti-Cancer Therapy, Mar 2017, UMMC, KUALA LUMPUR.., MSCT 2017, UMMC, MOS, MOH, UKM (National) (04 Mar 2017 - 05 Mar 2017)
  10. The Current Trend in SRE Prevention in Patients with Bone Metastasis from Prostate Cancer., Section of Uro-Oncology Forum, MUA, MOS (National) (30 Apr 2016 - 30 Apr 2016)
  11. Not applicable., Preceptorship Programme on Renal Cell Carcinoma - in Collaboration with British Columbia Cancer Centre Canada., Pfizer Oncology, BC Cancer Agency Canada (International) (27 Nov 2015 - 28 Nov 2015)
  12. Breast Cancer Updates., 2015 MOS Annual Scientific Meeting : Evolving Trends in Oncology - From Molecules to Man., Malaysia Oncology Society (International) (17 Oct 2015 - 18 Oct 2015)
  13. Xeloda in Metastatic Breast Cancer, Second Xeloda Preceptorship, Department of Clinical Oncology, UMMC & Roche (International) (11 Nov 2014 - 14 Nov 2014)
  14. A practical approach to optimizing new treatment., Clinical Conversations in mCRPC. , Janssen Oncology (National) (21 Jun 2014 - 21 Jun 2014)
  15. Metastatic Breast Cancer: What can we do today for patients?, Asian Oncology Summit, AOS, Elsevier (International) (11 Apr 2014 - 13 Apr 2014)
  16. Preventing SREs in Practice : How early is early in patients with bone metastases., Asian Oncology Summit, AOS, Elsevier (International) (11 Apr 2014 - 13 Apr 2014)
  17. Metastatic CRC : Maintenance treatment or stop-and-go. Which is better?, Colorectal Cancer Workshop, Department of Clinical Oncology, Merck (National) (29 Mar 2014 - 29 Mar 2014)

ACADEMIC/PROF. SERVICES


Evaluation
  1. (2023) Editorial Board Member, International, (Reviewer)
  2. (2018) Expert Panel : Advanced Prostate Cancer Consensus Conference (APCCC) Asia-Pacific (APAC) Satellite Symposium hosted by ANZUP Cancer Trials Group. , (Expert Panel)
  3. (2018) Reviewer : PSA kinetic as a prognostic in metastatic prostate cancer receiving ADT : systematic review and meta-analysis , (Reviewer)
  4. (2018) Expert Panel : Malaysian Consensus on the Advanced Prostate Cancer Consensus Conference (APCCC) 2017 Applicability in Malaysian Setting., (Expert Panel)
  5. (2014) Evaluator : Combination Effect of Metformin and FEC Chemotherapy on Breast Cancer, MMedSc UM, SSS. , (Candidature Defense Evaluator)
  6. (2014) Expert Panel : Depression in Cancer Patient from the Perspective of a Teaching Hospital in Malaysia, MD PhD UM, NCG. , (Seminar Panel)
  7. (2012) Reviewer : Dramatic and prolonged PSA response with a PSA vaccine. , (Reviewer)
  8. (2006) Internal Examiner : Master of Clinical Oncology University Malaya. , (Internal Examiner)
  9. Advisor : Phase II Study on the Effect of Oral Gamma-Tocotrienol (G-T3) Supplementation on the Overall Survival and Circulating Tumour Cells (CTC) in Subjects with Castration-Resistant Prostate Cancer (CRPC) , (Evaluate research protocol)
Contribution to external organisation
  1. (2021) Johnson&Johnson : Acexclusive2 - Asia Pacific Prostate Cancer Conference, International, (Resource Person)
  2. (2021) Johnson&Johnson : Southeast Asia Prostate Cancer Core (Pacer) Faculty Meeting., International, (Resource Person)
  3. (2021) Viatris : Gcsf - Biosimilar Advisory Board Meeting., National, (Expert Advisor)
  4. (2021) Merck : Management of Urothelial Carcinoma & Renal Cell Carcinoma in Malaysia - Advisory Board Meeting, National, (Expert Advisor)
  5. (2021) Eisai : Prognostic Risk Classifications and Its Implications in Treatment of Advanced Renal Cell Carcinoma., International, (Expert Advisor)
  6. (2021) Cipla : Roundtable Meeting - Role of Abiraterone in Prostate Cancer Patients., International, (Expert Advisor)
  7. (2021) Ipsen : Rcc Training by Medical Expert., National, (Expert Advisor)
  8. (2021) Eisai : Asian Renal Cancer Advisory Board Meeting., International, (Expert Advisor)
  9. (2018) Panelist for Advanced Prostate Cancer Consensus Conference (APCCC) - Asia-Pacific (APAC) Satellite Symposium., ANZUP Cancer Trials Group, International
  10. (2011) Associate Member, UMCRI, University
  11. (2006) Investigator, Clinical Investigation Centre UMMC, University
Contribution to event
  1. (2024) Scientific Committee Track Co-Chair for Genitourinary Symposium - Esmo Asia Congress 2024, International, (Event Organiser)
  2. (2024) Panellist - The Role of Multi-Disciplinary Team in Metastatic Prostate Cancer, National, (Panelist/Moderator)
  3. (2023) Scientific Committee for Gu Track - Esmo Asia 2023, International, (Event Organiser)
  4. (2023) Panelist - Malaysia Prostate Cancer Consensus 2022 (Mypcc 2022), International, (Panelist/Moderator)
  5. (2023) Panelist - Advanced Prostate Cancer Consensus Conference (Apccc) Asia-Pacific (Apac) Satellite Symposium, International, (Panelist/Moderator)
Mentoring
  1. (2022) Chen May Feng - Outcome of Observational Study On Acute Skin Toxicity Associated With Hypofractionated Radiotherapy to Whole Breast Based On UK Fast Forward Protocol., University, (Mentor)

SUPERVISION


Postgraduate Student
PhD/ Doctoral
  1. (2024) DEEP LEARNING FOR AUTOMATION OF CONTOURING AND IMAGE -GUIDANCE RADIOTHERAPY OF PROSTATE CANCER, NUR DIYANA AFRINA BINTI MOHD HIZAM
Master
  1. (2018) Project to be confirmed., Noor Nabila Binti Mohamad
  2. (2018) Project to be confirmed., Mohd Fahim Bin Abd Rahman
  3. (2018) Project to be confirmed., Izzati Binti Rosli
  4. (2017) The use of tiger milk mushroom (TM02) in improving quality of life for end-stage breast cancer patients., Eng Jie Yi
  5. (2017) Prospective Randomised Study of Pharmacokinetics of Low-Dose Abiraterone taken with Low-Fat Malaysian Breakfast Diet Versus Standard Dose Abiraterone Taken At Fasting in Metastatic Castrate Resistant Prostate Cancer and Metastatic Castrate Sensitive Prostate Cancer Patients., Tun Mohd Azlan Bin Mohamed Nor
  6. (2017) Project to be confirmed., Rizma Binti Mohd Zaid
  7. (2017) Project to be confirmed., Nurul Iman Binti Fathi
  8. (2017) Outcome of Patients with Glioblastoma Multiforme in UMMC., Nur Fa'izah Binti Ab Muin
  9. (2016) Prospective Study of Patiens with Spinal Cord Compression., Patricia Shamani
  10. (2016) Denosumab versus Zoledronic Acid in Prevention of ymptomatic Skeletal Events in Patients with Bone Metastases - UMMC Experience 2013-2015., Syafirin Ab Sani
  11. (2016) Clinical Supervision, Sangeeta A/P Vahnalingam
  12. (2016) Clinical Supervision, Najihah Abu Bakar
  13. (2016) Clinical Supervision, Lee Dai Wee
  14. (2016) Clinical Supervision, Eznal Izwal Mohd Mahidin
  15. (2016) Clinical Supervision, Ang Tick Suan
  16. (2016) An Audit on Treatment Outcome of Bladder Carcinoma in UMMC., Vance Koi Yung Chean
  17. (2015) Palliative Oncological Treatment Near End of Life : A UKMMC Experience., Ngu Ming Ruey
  18. (2015) Outcome of Treatment with SRS in Patients with Brain Metastases., Lee Hong Moi
  19. (2015) Outcome of Metastatic Castrate Resistant Prostate Cancer on Taxane Chemotherapy, Junie Khoo
  20. (2015) Clinical Supervision, Sucharit Pongprakyun
  21. (2015) Clinical Supervision, Marfuah Nik Eezamuddeen
  22. (2015) Clinical Supervision, Malwinder Singh Sandhu
  23. (2015) Clinical Supervision, Leong Siew Mooi
  24. (2015) Clinical Supervision, Junie Khoo Yu Yen
  25. (2014) Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective, Tang Weng Heng
  26. (2014) Clinical Supervision, Tang Weng Heng
  27. (2014) Clinical Supervision, Nahjatul Kursyiah Abd Ghafar
  28. (2013) Treatment Outcome of Patients with Malignant Spinal Cord Compression in UMMC 2010-2015., Choong Swee Hsia
  29. (2013) Hormonal Therapy in Metastatic Prostate Cancer, Prathepamalar AP Yehgambaran
  30. (2013) Evaluation of Patient Satisfaction after First Consultation in Oncology Clinic in UMMC., Khairiyah Binti Sidek
  31. (2013) Clinical Supervision, Wong Yoke Fui
  32. (2013) Clinical Supervision, Noor Zafifah Binti Zakaria
  33. (2013) Clinical Supervision, Muthukkumaran A/L Thiagarajan
  34. (2013) Clinical Supervision, Lim Chun Sen
  35. (2013) Clinical Supervision, Harissa Husainy Hasbullah
  36. (2013) Clinical efficacy and tolerability of targeted therapy in Malaysian patients with metastatic renal cell cancer, Nahjatul Kursyiah Bt Abd Ghafar
  37. (2012) Treatment Outcomes of Patients with Inoperable or Metastatic Gastrointestinal Stromal Tumours Treated with Imatinib: A Multicenter Study., Vaishnavi Jeyasingam
  38. (2012) Treatment outcome in metastatic prostate cancer patients treated with androgen deprivation therapy in UMMC., Prathepamalar A/P Yehgambaram
  39. (2012) Clinical Supervision, Vaishnavi Jeyasingam
  40. (2012) Awareness of Cognitive Changes & Impact on Functioning at Work : A Qualitative Study in Women with Breast Cancer., Maryam Hafsah Mohammed Selamat
  41. (2011) Single vs multiple fraction palliative radiotherapy for uncomplicated painful bone metastases treated at University of Malaya Medical Centre: A single institutional Malaysian experience, Ina Shaliny Duraisamy
  42. (2011) Clinical Supervision, Winnie Ng Nyek Ping
  43. (2011) Clinical Supervision, Suhana Yusak
  44. (2011) Clinical Supervision, Santhi Nadarajan
  45. (2011) Clinical Supervision, Ng Boon Huat
  46. (2011) Clinical Supervision, Natasha Mohd Hashim
  47. (2011) Clinical Supervision, Fong Chin Heng
  48. (2011) Clinical Supervision, Cheah Soon Keat
  49. (2010) Prospective controlled trial of scalp hypothermia to prevent chemotherapy-induced alpecia in patients with breast cancer receiving anthracycline or taxane-based chemotherapy., Flora Chong Li Tze
  50. (2010) Clinical Supervision, Yu Kong Leong
  51. (2010) Clinical Supervision, Wan Zamaniah Wan Ishak
  52. (2010) Clinical Supervision, Tan Chih Kiang
  53. (2010) Clinical Supervision, Lee Wei Ching
  54. (2010) Clinical Supervision, Kua Voon Fong
  55. (2010) Clinical Supervision, Ibtisam Muhammad Nur
  56. (2010) Clinical Supervision, Hayani Abdul Wahid
  57. (2010) Clinical Supervision, Hafizah Zaharah Ahmad
  58. (2010) Clinical Supervision, Flora Chong Li Tze
  59. (2010) Clinical Supervision, Arnil George Sirimanne
  60. (2009) Outcome of Localised Soft Tissue Sarcoma in UMMC., Lau Kah Liew
  61. (2009) Clinical Supervision, Ros Suzanna Ahmad Bustamam
  62. (2009) Clinical Supervision, Mastura Md Yusof
  63. (2009) Clinical Supervision, Lau Kah Liew
  64. (2008) Pattern of recurrence for non-metastatic invasive breast cancer in UMMC, Rozita Abdul Malik
  65. (2008) Clinical Supervision, Rozita Abdul Malik
  66. (2008) Clinical Supervision, Chan Wee Han
  67. (2007) Clinical Supervision, Vincent Phua Chee Ee
  68. (2007) Clinical Supervision, Nik Muhd Aslan Abdullah
  69. (2007) Clinical supervision, Fabian Lee Wei Yuen

TEACHING


Master
  1. (2019) MGT - Master of Clinical Oncology
  2. (2018) MGT - Master of Clinical Oncology
  3. (2017) MGT - Master of Clinical Oncology
  4. (2016) MCO - Master of Clinical Oncology
  5. (2015) Master of Clinical Oncology
  6. (2014) Master of Clinical Oncology
  7. (2013) Masters of Clinical Oncology
  8. (2012) Masters of Clinical Oncology
  9. (2011) Master of Clinica Oncology
  10. (2011) Masters of Clinical Oncology
  11. (2010) Masters of Clinical Oncology
  12. (2010) Masters of Medical Physics
  13. (2009) Master of Clinical Oncology
  14. (2007) Master of Clinical Oncology
  15. (2006) Master of Clinical Oncology
Bachelor
  1. (2017) UMMP - Bachelor of Medicine
  2. (2016) UMMP - Bachelor of Medicine
  3. (2015) Bachelor of Medicine UM (Ummp)
  4. (2014) Bachelor of Medicine UM (Ummp)
  5. (2013) Bachelor in Medicine : Elective Attachment
  6. (2013) Bachelor of Medicine - Elective
  7. (2007) MTEJ3102 - Degree in Nursing
  8. (2006) MTEJ3102 - Degree in Nursing
  9. () UMMP - Bachelor of Medicine
Others
  1. (2008) ADNS3001 - Advanced Diploma in Oncology Nursing
  2. (2006) ADNS3001 - Advanced Diploma in Oncology Nursing

SOCIAL RESPONSIBILITY ACTIVITIES


  • Speaker - Effectiveness of Cancer Treatment Based On New Updates - Nursing Workshop in Oncology - Close The Gap in Cancer Care., (27 Feb 2024 - 27 Feb 2024) (National)
  • Mos Cancer Fun Run 2024, (21 Jan 2024 - 21 Jan 2024) (National)
  • Bike Ride Challenge in Singapore to Raise Fund and Awareness for Prostate Cancer, (02 Dec 2023 - 02 Dec 2023) (International)
  • Panelist for Gp Training On Prostate Cancer Management, (20 Oct 2023 - 20 Oct 2023) (National)
  • Blue Cap Relay Run to Raise Fund for Prostate Cancer, (24 Sep 2023 - 24 Sep 2023) (National)
  • Fundraising Gala Dinner by Faculty of Medicine to Raise Fund for Students Learning Facilities, (18 Mar 2023 - 18 Mar 2023) (University)
  • Patient Education On Prostate Cancer, (01 Jan 2023 - 29 Feb 2024) (National)
  • Panelist At The Bald & Beautiful Public Forum On Genetics and Cancer - There Are 50,000 Angelina Jolie in Malaysia Ad Half of Them Are Men., (02 Dec 2021 - 02 Dec 2021) (National)
  • Panelist At Public Forum On Covid19 Vaccine and Cancer Patients - What Happens After Covid19 Vaccination?, (11 May 2021 - 11 May 2021) (National)
  • Speaker At Pcsm Annual General Meeting : Prostate Cancer - All You Want to Know About Chemotherapy., (28 Mar 2021 - 28 Mar 2021) (National)
  • Teaching Session With The Hospis Malaysia Clinical Team : The Role of Immunotherapy in Advanced Cancer., (17 Mar 2021 - 17 Mar 2021) (National)
  • Expert Panel Discussing On Prostate Cancer - Tiga Langkah Elakkan Kanser Prostat, Sinar Harian Online, 22 November 2020., (22 Nov 2020 - 22 Nov 2020)
  • Expert Panel On Webinar On Prostate Cancer, Di Sebalik Movember - Apa Anda Perlu Tahu Tentang Kanser Prostat, Astro Awani, 18 November 2020., (18 Nov 2020 - 18 Nov 2020)
  • Advisor On The Content of Information for Public On Prostate Cancer Campaign #Onlymencan_nov 2020., (01 Nov 2020 - 30 Nov 2020)
  • Delivered a Lecture On Does My Genetic Profile Impact My Treatment in a Webinar for The Public At Together Against Cancer Public Forum 18th October 2020, Organised by Universiti Malaya and Cancer Research Malaysia., (18 Oct 2020 - 18 Oct 2020)
  • Delivered a Lecture On Agnostic Genetic Testing for Precision Medicine in Oncology in a Webinar - 18 October 2020, Organised by Universiti Malaya and Cancer Research Malaysia., (18 Oct 2020 - 18 Oct 2020)
  • Invited Panel At Prostate Cancer Society Malaysia Meeting - 3rd October 2020., (03 Oct 2020 - 03 Oct 2020)
  • Trainer At Advanced Urology Training Course for Urology Fellows - 15 Sep 2020, Malaysia Urology Association., (05 Sep 2020 - 05 Sep 2020)
  • Chair At Cancer Survivorship Forum, 15 February 2020, Umric UM., (15 Feb 2020 - 15 Feb 2020)
  • Expert Panel At Prostate Cancer Support Group Meeting, 4th July 2019 University Malaya Medical Centre. Prostate Cancer : Newer and Future Treatment., (04 Jul 2019 - 04 Jul 2019)
  • Guest Speaker for Oncology Colloquium by Malaysian Medics International, 3-4th Feb 2018, Ummc., (03 Feb 2018 - 04 Feb 2018)
  • Guest Participant At Ummc Candy Girls Year End Party (Breast Cancer Support Group), 30-31 December 2017., (30 Dec 2017 - 31 Dec 2017)
  • Advisor for Oncology Colloquium by Malaysian Medics International, 3-4th Feb 2018, Ummc., (01 Nov 2017 - 28 Feb 2018)
  • Panel Speaker for Specializing Opportunities Symposium by Malaysian Medics International, 29-30 August 2017, Kuala Lumpur., (29 Aug 2017 - 30 Aug 2017)
  • Panel Speaker for Prostate Cancer Seminar by Prostate Cancer Society Malaysia - Management of Localised and Metastatic Prostate Cancer, 9 August 2017, Ummc., (09 Aug 2017 - 09 Aug 2017)
  • Panel Speaker for Malaysian Enterostomal Therapy Nursing Education Programme (Metnep) - Role of Chemotherapy and Radiotherapy in Cancerous Wounds and Stoma Care, 20 May 2017, Ummc., (20 May 2017 - 20 May 2017)
  • Involved in Candy Girls Fitness Event Dance Into 2017, Dec 2016., (31 Dec 2016 - 31 Dec 2016)
  • Mc Cooking for Success - Workshop for 3rd Ummc Breast Cancer Public Forum Oct 2016., (22 Oct 2016 - 22 Oct 2016)
  • Spoke On Iort At 3rd Ummc Breast Cancer Public Forum Oct 2016., (09 Oct 2016 - 09 Oct 2016)
  • Organizing Committee for 3rd Ummc Breast Cancer Public Forum Oct 2016., (09 Oct 2016 - 09 Oct 2016)
  • Spoke At The Prostate Cancer Support Group Event Oct 2016., (01 Oct 2016 - 01 Oct 2016)
  • Advisor for Onco-Lead Workshop Aug 2016 - First Workshop for Trainees & Medical Officers in Oncology., (20 Aug 2016 - 20 Aug 2016)
  • Sharing Session With Hospis Malaysia Team Aug 2016., (17 Aug 2016 - 17 Aug 2016)
  • Gave Training On Shared Decision Making At The Ummc-Esg Programme Aug 2016., (13 Aug 2016 - 13 Aug 2016)
  • Chairperson of Committee for Oncology Dept Family Day Jul 2016., (30 Jul 2016 - 30 Jul 2016)
  • Gave a Lecture On Oncological Treatment At The Malaysian Hospice Congress Apr 2016., (22 Apr 2016 - 24 Apr 2016)
  • Article On Prostate Cancer in The Sunday Star 22 November 2015 : Choice in Prostate Cancer - Decoding Your Choice of Care for Prostate Cancer., (22 Nov 2015 - 22 Nov 2015)
  • Chairperson for The 2nd Ummc Breast Cancer Public Forum Oct 2015., (25 Oct 2015 - 25 Oct 2015)
  • Featured as An Expert Panel in 23rd Asia Pacific Cancer Conference Bulletin : Heterogeneity of Prostate Cancer - a Guide to Treatment Choice., (21 Aug 2015 - 23 Aug 2015)
  • Training for Candy Girls Breast Cancer Survivors - Reaching to Recovery May 2015., (09 May 2015 - 09 May 2015)
  • Medical Advisor to Candy Girls Breast Cancer Survivor Support Group Ummc., (09 May 2015 - 31 May 2016)
  • Educational Talk to Breast Cancer Survivors in a Pink Ribbon Event : How to Prevent Breast Cancer Recurrence., (20 Mar 2015 - 20 Mar 2015)
  • Participation in Pink Ribbon Event for Breast Cancer Survivors - How to Prevent Recurrence., (19 Mar 2015 - 21 Mar 2015)
  • Invited Panel At The First Ummc Breast Cancer Public Forum 18 Oct 2014 : Why Do I Need Chemotherapy - Factors That Affect Outcome., (18 Oct 2014 - 18 Oct 2014)
  • Expert Panel On National Radio Station Bfm, The Bigger Picture - Kidney Cancer and Its Treatment Development. Http://WWW.Bfm.My/Marniza-Saad-Kidney-Cancer.Html, (26 Jun 2014 - 26 Jun 2014)
  • Annual Scientific Conference of Malaysia Oncology Society (Ascomos) Nov 2013 : Chairperson., (29 Nov 2013 - 01 Dec 2013)
  • Annual Scientific Conference of Malaysia Oncology Society (Ascomos) Nov 2013 : Scientific Committee., (29 Nov 2013 - 01 Dec 2013)
  • Walk for Life to Help Children With Leukaemia., (17 Nov 2013 - 17 Nov 2013)
  • Musculoskeletal Imaging and Oncology Conference June 2013 : Chairperson for Free Paper Session., (13 Jun 2013 - 15 Jun 2013)
  • Musculoskeletal Imaging and Oncology Conference June 2013 : Coordinator for Oncology Track., (13 Jun 2013 - 15 Jun 2013)
  • Featured in Health and Beauty Magazine, June 2013 Issue : Targeted Therapies for Cancer Care., (01 Jun 2013 - 30 Jun 2013)
  • Help Mapcu Organ Donation Run 2013 (7km), (26 May 2013 - 26 May 2013)
  • Asian Breast Cancer Summit 2013 : Chair for Session 'Beyond Conventional Treatment in Pre-Treated Metastatic Breast Cancer'., (12 Apr 2013 - 12 Apr 2013)
  • Featured in Health Today Magazine Feb 2013 Issue : Article On The Treatment of Prostate Cancer as Part of Prostate Cancer Awareness Campaign., (01 Feb 2013 - 28 Feb 2013)
  • Featured in Newspaper : Metro Ahad - Article On Prostate Cancer : `Kanser Ditakuti Lelaki'., (06 May 2012 - 06 May 2012)
  • Featured in National Newspaper : Article On New Treatment for Prostate Cancer., (29 Apr 2012 - 29 Apr 2012)
  • Chemotherapy Booklet for Patients, (02 Jan 2012 - 31 Dec 2012)
  • Featured in Oncology Tribune, July 2010 : Article On Renal Cancer Treatment - `Mtt Improves Survival Rate in Renal Cell Carcinoma'., (01 Jul 2010 - 01 Jul 2010)
  • Invited Expert Panel On National Tv Station : Hello Malaysia - Breast Cancer., (27 Aug 2009 - 27 Aug 2009)
  • Participation in Jacob's Walk of Life to Promote Healthy Lifestyle., (24 Jun 2007 - 24 Jun 2007)